[{"article": "A response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nThe procedure is noninvasive and doesn't require anesthesia, and the pulses are delivered via an electromagnetic device or coil that is placed or worn on the head.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe Food and Drug Administration made the announcement on Friday, expanding the use of a technology that has been around for decades.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that TMS and TMS devices aren\u2019t new, but this is the first time a TMS device can be marketed as an OCD treatment.\nHowever, the story says \u201cthere\u2019s no equivalent device already available to patients,\u201d but that doesn\u2019t appear to be accurate. There are several brands of TMS devices. Is there anything unique about this one for OCD, or was Brainsway simply the first to test it on OCD patients?", "answer": 1}, {"article": "But in Vertex\u2019s trial, about 70 percent of those who achieved an effective cure were able to do so in 24 weeks, or about six months.\nMost of the other new drugs also work by blocking viral enzymes.\nIt is so arduous that many patients opt not to get treated or drop out before completing the course.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\nThe disease can cause cirrhosis, which is a scarring of the liver, as well as liver cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The storyt makes clear that this is a new treatment that is not yet FDA approved \u2013 a novel agent and class.", "answer": 1}, {"article": "Although the U.S. Centers for Disease Control and Prevention recommends that 11- and 12-year-old girls begin receiving the vaccine as part of school vaccination efforts, an advisory panel voted against routine use of the vaccine in boys and men.\nHPV is almost ubiquitous in males and females, but experts note that most people will clear the virus naturally so that it does not result in any harm.\nAccording to a study presented last year by researchers at the University of Maryland, just one-third of teen girls and young women who start the three-dose series actually finish, and almost three-quarters don't start it at all.\n\"We're going to finally be able to see men benefit from vaccine, as women have, in coming years,\" said Giuliano.\nThe researchers also saw some reduction in the number of precancerous penile lesions, although at this point they said it's impossible to know whether this will result in a lower rate of penile cancers.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not provide any information about the novelty of Gardasil, one of the first vaccines of its type. It also does not mention that there is another vaccine, Cervarix, which also exists against some HPV. WebMD did a better job of this. ", "answer": 0}, {"article": "At least 135,587 adverse drug reactions linked to antidepressants were reported to the Food and Drug Administration's Adverse Event Reporting System between 2004 and 2012.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\nAccording to a study conducted by the Mayo Clinic that looked at one genetic test similar to many used in hospitals \u2014 GeneSight Psychotropic \u2014 symptoms of depression were reduced by 70 percent compared to treatments prescribed without genetic testing.\nThey can couple their expert opinions with information from the patient, like their symptoms and family history, to look more closely at one class of drug over another.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story includes no information about how the Genefolio test differs, if at all, from any other genetic tests currently available.", "answer": 0}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly cites usage data since 2002, so it\u2019s clear this is not a just-unwrapped product or procedure.", "answer": 1}, {"article": "All participants took calcium and vitamin D as well.\nAccording to an editorial accompanying the study, this complication occurs in about 5 percent of cancer patients who are taking a high-dose bisphosphonate (Zometa or Aredia) to control or prevent spread of malignancy to the bone.\n\"These were patients with severe periodontal disease but who were otherwise systemically healthy,\" said study senior author Dr. Laurie K. McCauley, chair of the department of periodontic and oral medicine at the University of Michigan in Ann Arbor.\n\"I think that it's really an important important proof-of-concept that you can inject locally and get a response,\" said Dr. Rena D'Souza, chair of biomedical sciences at Texas A&M Health Science Center Baylor College of Dentistry in Dallas.\nThe editorial pointed out, however, that Forteo should not be used in patients whose cancer has already spread to the bone, as it might prompt even more spread.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article explains that Forteo is not approved by the FDA for osteonecrosis or the form of gum disease assessed in the randomized study. It could have noted that previous studies have suggested that Forteo may be of value in the treatment of osteonecrosis.", "answer": 1}, {"article": "Atrial fibrillation affects more than 2.6 million people in the United States.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\nThe findings suggest that the current risk scoring systems for tailoring anti-clotting (anticoagulant) treatment to individual patients may be less relevant when using apixaban for patients with atrial fibrillation who have at least one risk factor for stroke, according to the Duke University Medical Center researchers.\n\"The benefits of apixaban are preserved, regardless of the risk score used and regardless of the patient risk category,\" study author and cardiologist Dr. Renato Lopes said in a Duke news release.\nMONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes a very bold claim by quoting the press release about the study. It says, \u201cWith new oral anticoagulants, such as apixaban, we might not need risk scores to guide treatment decisions for stroke prevention in patients with atrial fibrillation. This may simplify how physicians make decisions and also improve patient care.\u201d The implication is clear: Throw away risk scores because apixaban is just that safe. The story does not provide enough evidence to let that claim go unchallenged.", "answer": 0}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that this is one of many attempts to find a treatment for Alzheimer\u2019s.", "answer": 1}, {"article": "The study had several limitations.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\nEarlier studies had suggested that aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may help protect against colorectal cancer, but it wasn\u2019t clear how much had to be taken, and for how long, to achieve those benefits.\nAlso, the researchers can\u2019t rule out the possibility that other factors may have increased participants\u2019 risk for colorectal cancer, such as obesity, dietary habits, alcohol use, and family history of colorectal cancer.\n\u201cUnless low-dose aspirin is taken continuously, there is little protection against colorectal cancer,\u201d Dr. Soren Friis from the Danish Cancer Society Research Center in Copenhagen told Reuters Health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "High up in the story, the reader is told what is new about this study:\u00a0\u201cEarlier studies had suggested that aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may help protect against colorectal cancer, but it wasn\u2019t clear how much had to be taken, and for how long, to achieve those benefits.\u201d", "answer": 1}, {"article": "Yet the ultimate goal of prevention is to save lives.\nThe amount of benefit he\u2019ll get is not much, but his risk reduction still is 25 or 30 percent.\u201d\n\nDr. Thompson knows what he will do about finasteride.\n\u201cFinasteride has to be recognized as the first clearly demonstrated way to prevent prostate cancer with any medication or any oral agent at all.\u201d\n\nFinasteride has had its ups and downs.\nBut the reality is that people are being operated on.\u201d\n\n\u201cWe are trying to avoid a diagnosis to avoid a prevention whose value is disputed,\u201d he said.\n\u201cThe data are compelling,\u201d said Dr. Peter Scardino, chairman of the department of surgery at Memorial Sloan-Kettering Cancer Center, a convert who originally thought the drug was dangerous.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story begins with the phase \"For the first time\u2026.\" \u2013 an odd choice of words for an effect of the drug that was discussed in the medical literature for at least 3 years. \u00a0Although the story was about the results of a new analysis of data, that opening line suggests a novelty to the approach that isn\u2019t true.\u00a0 In fact, the story itself shows it\u2019s not the first time \u2013 that \"In March 2003, 15 months before the study\u2019s scheduled end, its directors halted it abruptly. The reason was that the results were overwhelmingly compelling \u2014 men taking the drug were not getting prostate cancer.\"\u00a0 It\u2019s like an opening line begging for page 1 attention.\u00a0 ", "answer": 0}, {"article": "WEDNESDAY, Sept. 8, 2010 (HealthDay News) -- Statins, lauded for their ability to lower cholesterol and prevent heart attacks and strokes, may also reduce the risk of developing rheumatoid arthritis, Israeli researchers report.\nThe researchers looked for connections between statin use and the development of both rheumatoid arthritis and osteoarthritis, a degenerative joint disease that is unlikely to be affected by statins, the researchers noted.\nAfter looking for other possibilities, those who took statins regularly had a 41 percent lower risk of developing rheumatoid arthritis compared with people who were not taking statins regularly.\n\"We believe that a major part of the improved survival among statin users comes from the anti-inflammatory effects demonstrated by lower risk of rheumatoid arthritis.\nWhen Chodick's group looked at statin use, they found that those not taking statins had a 51 percent higher risk of developing rheumatoid arthritis over about 80 percent of the follow-up period.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nWhile the story refers to earlier research on statins by the same group, it fails to mention other studies that specifically looked at any links between statin use and rates of rheumatoid arthritis, thus implying that this study may be the first one.", "answer": 0}, {"article": "Dr. Michael Rosenbaum, the lead investigator, said the 10-week study was too short and too small to determine whether continuous leptin treatments could allow dieters to keep off their weight permanently and effortlessly.\nThey also usually stop losing weight and often gain back what they have already lost.\n\"Obesity is the one disease I can think of where your body fights the cure,\" he said.\nThey also have much lower levels of the fat hormone, leptin.\nEveryone who has dieted knows that losing weight is the easy part.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Doesn\u2019t mention that leptin \nis a purely experimental treatment \u2013 a hormone discovered in 1969.", "answer": 0}, {"article": "Overall, the studies involved nearly a million participants.\nResearchers say the number of people with type 2 diabetes is expected to increase by 65% by 2025, reaching an estimated 380 million people worldwide.\nThe results showed that people who drink more coffee, whether it\u2019s regular or decaffeinated, or tea appear to have a lower risk of developing type 2 diabetes.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\nThe study also showed that people who drank more than three to four cups of decaffeinated coffee per day had about a one-third lower risk of developing type 2 diabetes than those who didn\u2019t drink any.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0This story stated that, \"several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\"", "answer": 1}, {"article": "SUNDAY, Dec. 5, 2010 (HealthDay News) -- Using gene therapy, German researchers report that they managed to \"correct\" a malfunctioning gene responsible for Wiskott-Aldrich syndrome, a rare but devastating childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children vulnerable to certain cancers and dangerous infections.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\nIn this study, the researchers inserted a healthy gene capable of producing WAS protein into hematopoietic stem cells (the \"granddaddy\" cells that give rise to different blood cells), then transferred these stem cells back into the patient using a viral vector.\nThe study was based on questionnaires returned from more than 12,500 donors, which also showed the donors tended to be in good health and were willing to donate again.\nAnother study found that the drug rituximab (Rituxan), used to treat rheumatoid arthritis and forms of leukemia and lymphoma, could greatly reduce graft-versus-host disease in stem cell transplant recipients.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story never mentioned that gene therapy using viral vectors is being studied for the treatment of a variety of other hereditary diseases as well as cancer. Importantly, this research has shown that it is extremely\u00a0difficult to develop effective therapies based on viral vectors \u2014 context that would have been valuable in this story.", "answer": 0}, {"article": "Related: What Really Helps Knee Pain?\n\"It erased all of that.\u201d\n\nThe outpatient procedure typically takes about 40 minutes, is performed with local anesthesia and doesn\u2019t require an incision.\nThe three current recommended approaches for knee arthritis pain are physical therapy, non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen, or the opioid painkiller tramadol.\nThe treatment, recently approved by the Food and Drug Administration, is called \u201ccooled radio frequency ablation\u201d and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that don\u2019t make them a good candidate for surgery.\nFor some patients with structural problems of the knee, the procedure won't help, said pain specialist Dr. Edgar Ross, associate professor of anesthesia at Brigham and Women\u2019s Hospital.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This use of radiofrequency treatment on arthritic knees does appear to be relatively new, although the technique has been employed to cope with a variety of other painful conditions, including trigeminal neuralgia, cancer pain, and spinal pain.\nAlthough radiofrequency therapy is over 60 years old, it is not used very often, apart from some procedures by cardiologists to rewire the heart\u2019s electrical system.", "answer": 1}, {"article": "But researchers say the preliminary findings could one day lead to diabetes treatments.\n\u201cCertainly weight loss by any means improves type 2 diabetes, but there is something else going on with gastric bypass surgery,\u201d study researcher Blandine Laferrere, MD, of Columbia University\u2019s St. Luke\u2019s and Roosevelt Hospital Center, tells WebMD.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nWhen researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Gastric bypass is not novel and the story \u2013 in reporting that 200,000 people have it each year \u2013 did not portray it as such.\nTurning improved understanding about branched chain amino acids impacting diabetes into an effective treatment for diabetes is at this time hypothetical and was discussed as having potential for use.", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThe article explains that minimally invasive hip replacements are relatively new and were \u201cpioneered in the early part of this century.\u201d", "answer": 1}, {"article": "2013: New guidelines could have far more Americans taking statin drugs for cholesterol\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of whether they have a history of cardiovascular disease.\nThere is a consensus among experts that people at substantial risk for heart disease benefit from statins but considerable disagreement about those at lower risk.\nThey are more likely to not only get to the hospital and survive until they are discharged but also survive in greater numbers a year after their hospitalization than those who do not use statins.\nThe task force, which is made up of independent experts but commissioned by the government, concurred after a comprehensive review of the evidence on the topic determined that a broader evaluation of risk is needed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes novelty of the task force report by explaining:\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of\u00a0whether they have a history of cardiovascular disease.", "answer": 1}, {"article": "The FDA said Kybella demonstrated safety and efficacy in two clinical trials involving more than 1,000 adults.\nA reduction in chin fat was \"observed more frequently\" in patients receiving the treatment than in those who got a placebo.\nThe drug, Kybella, is a form of synthetically derived deoxycholic acid, which the body produces naturally to help absorb fats.\nA top example: Annual sales of the anti-wrinkle drug Botox have surged to $2 billion in recent years.\nThe most common side effects included swelling, bruising, pain, numbness, redness and areas of hardness in the vicinity of the injection.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear about what\u2019s new \u2014 a drug that destroys fat cells under the chin.", "answer": 1}, {"article": "The findings are mixed on substance abuse.\n\u201cIt\u2019s a shift from having our mental health defined by the content of our thoughts,\u201d Dr. Hayes said, \u201cto having it defined by our relationship to that content \u2014 and changing that relationship by sitting with, noticing and becoming disentangled from our definition of ourselves.\u201d\n\nFor all these hopeful signs, the science behind mindfulness is in its infancy.\nA recent review by Canadian researchers, focusing specifically on mindfulness meditation, concluded that it did \u201cnot have a reliable effect on depression and anxiety.\u201d\n\nTherapists who incorporate mindfulness practices do not agree when the meditation is most useful, either.\n\u201cWhat concerns me is the hype, the talk about changing the world, this allure of the guru that the field of psychotherapy has a tendency to cultivate.\u201d\n\nBuddhist meditation came to psychotherapy from mainstream academic medicine.\nThe question, said Linda Barnes, an associate professor of family medicine and pediatrics at the Boston University School of Medicine, is not whether mindfulness meditation will become a sophisticated therapeutic technique or lapse into self-help clich\u00e9.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides an historical perspective of mindfulness practices and discusses how the practice was popularized by Western practitioners.\u00a0 The story notes that incorporating mindfulness meditation or elements of the practice into psychotherapy has become more popular, but the value of this practice still needs to be studied, especially with more vulnerable patients. ", "answer": 1}, {"article": "\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nBut they found that the number of children born to a mother did not affect the results.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\n\u201cBreast-feeding for an entire year is difficult for many women,\u201d said Dr. Mitra Pikwer, the lead author and an intern at Malmo University Hospital in Malmo, Sweden.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nBreast-feeding has been around for millennia, and most readers know this.\n", "answer": 1}, {"article": "July 30, 2012 -- If it weren't for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\nIt finds that in the three years before widespread PSA testing (1983-1985), men getting their first diagnosis of prostate cancer were three times more likely to learn they had very late-stage cancer than men diagnosed in the most recent three years for which data is available (2006-2008).\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\n\"By not using PSA tests in the vast majority of men, you have to accept you are going to increase very serious metastatic disease threefold,\" says study leader Edward Messing, MD, chief of urology at the University of Rochester Medical Center.\nFor example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We react pretty strongly to the statement way up high in the 3rd sentence of the story:\u00a0 \u201cThe new study seems to make a powerful argument in favor of PSA testing.\u201d\u00a0 Even though that statement is countered 3 paragraphs later by Dr. Barry Kramer, the sentence may have set an early tone for readers that is difficult to overcome with later skepticism.\u00a0 Instead, why not put in the 3rd sentence of the story something about the limitations of such a statistical modeling analysis?\nWe admit we\u2019re hard line on this:\u00a0 but the framing of screening stories is important.", "answer": 0}, {"article": "The IVC required cross-clamping in 24 cases.\n\"This is a complex condition and the complication rate with open surgery is 12% to 47%, depending on the thrombus level, with a mortality rate of 5% to 10%,\" explained lead investigator Ronney Abaza, MD, Robotic Surgery Director at OhioHealth Dublin Methodist Hospital.\nRobotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes and reproducibility when performed by surgeons with adequate robotic experience, according to first multi-institutional report, published in the journal of urology\n\nNew York, NY, Feb. 7, 2016 - Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nHowever, despite the complex and critical nature of these procedures, our series demonstrates favorable outcomes and reproducibility by surgeons with adequate robotic experience.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release notes the history of the procedure and that this is the first multi-institutional study to examine the role of robotically assisted minimally invasive surgery for this condition.\nFrom the published study: \u201cWe report our combined experience with this procedure, to our knowledge the first multi-institutional and largest series reported to date.\u201d", "answer": 1}, {"article": "TUESDAY, Jan. 31, 2017 (HealthDay News) -- A breath test to detect stomach and esophageal cancers shows promise, researchers say.\nEach year, 1.4 million cases of cancer of the stomach and esophagus (the tube leading from the throat to the stomach) are diagnosed worldwide.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the esophagus and stomach, and which do not,\" he explained.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\nThis method is expensive, invasive and has some risk of complications,\" study author Dr. Sheraz Markar said in an ECC news release.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This isn\u2019t the first research to address the possibility of using breath tests to diagnose cancer, nor is it the first research to look at using breath tests to diagnose stomach cancer. A quick search finds other journal articles that use various techniques to approach the challenge of diagnosing cancer using a patient\u2019s breath (like this one, or this one). This may well be the first breath test to look at these specific chemicals in the breath, or the first breath test to show this degree of accuracy. However, we don\u2019t know that, because the story doesn\u2019t place the new research into context: How does it fit into the broader continuum of research on using breath tests to diagnose cancers?", "answer": 0}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that this is a newer procedure for breast augmentation and possibly breast reconstruction.\u00a0 Fat grafting is not new in cosmetic and reconstructive surgery. The additional of stem cells to a person\u2019s own fat is new and the story notes that long-term outcome of fat and stem cells in breast tissue is not known.\u00a0 ", "answer": 1}, {"article": "By the time most lung cancers are diagnosed -- which usually involves an invasive examination of the lungs -- patients already have advanced malignancies.\nAnd when treated with the compound myo-inositol, the gene pathway activity declined along with improvement in the troublesome lesions, the researcher noted.\nMaybe one day, screening could be done using an even simpler nasal or sputum test, the researchers said.\n\"We have identified a marker for an early risk of developing lung cancer.\"\nIt turned out that gene activity in the PI3K pathway was \"off the chart\" in smokers with lung cancer versus those without the disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Didn\u2019t put this new research into the context of any of the other lung cancer genetic expression research underway, so this story provides no context on the true novelty of this approach. ", "answer": 0}, {"article": "Feb. 1, 2010 -- Twelve weeks of fish oil pills made teens at high risk of psychosis much less likely to become psychotic for at least one year.\n\"The finding that treatment with a natural substance may prevent or at least delay the onset of psychotic disorder gives hope that there may be alternatives to antipsychotics for the prodromal phase [symptoms leading up to psychosis onset],\" Amminger and colleagues suggest.\nThe finding comes from a placebo-controlled clinical trial that enrolled 81 young people -- average age 16 -- teetering on the brink of psychosis.\nIt may be that fish oil works better in young people with pre-psychotic conditions than in older people with more established psychiatric disorders.\nThat's the same level of efficacy seen with antipsychotic medications, note study researcher G. Paul Amminger, MD, of the University of Vienna, Austria, and colleagues.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story does a nice job of setting the stage by saying that patients with psychriatric disorders have been found to have low levels of omega 3; hence the need for trials to study fish oil pills in these\u00a0patients.\u00a0 The story also points out that other studies have evaluated the effect of omega-3 fatty acids\u00a0on depression and other psychiatric disorders; however, the results of these studies have been mixed. ", "answer": 1}, {"article": "WASHINGTON (Reuters) - The U.S. Food and Drug Administration took a fresh step on Thursday towards setting a maximum nicotine level for tobacco products in a bid to lower tobacco-related deaths across the country, saying it would collect public comment and scientific research over the next three months.\nThat plan marked a major shift designed to give adult smokers a wider range of alternatives, including potentially less harmful e-cigarettes.\nThe agency is seeking to determine a level of nicotine in cigarettes and other tobacco products that would be minimally addictive or nonaddictive, according to a draft proposal.\nThe FDA will seek public input and scientific research on the role that flavors such as menthol play in tobacco addiction, and for the regulation of premium cigars, Gottlieb said.\nThe FDA will continue to take enforcement actions against companies that inappropriately target children, including through the promotion of e-cigarettes, Gottlieb said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes very clear that this is a new and sweeping effort by the FDA to reduce smoking rates in the US.", "answer": 1}, {"article": "This gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\nAnd right now, there is a way to go before most doctors will have those systems in place.\nIt also factored in what\u2019s known about different types of patients\u2019 responses to various blood pressure medications.\nIt found that the tailored approach could prevent 43 percent more heart attacks and strokes than the simpler, general recommendations used now.\n\u201cThis shows that there might be better ways for physicians to choose who gets treated and who does not,\u201d said Dr. Douglas K. Owens of the VA Palo Alto Health Care System in California, who wrote an editorial published with the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story could have done a better job providing even a brief background on the Archimedes system and past reports about this or related research. A reader might think this was the very first news about this approach.", "answer": 0}, {"article": "While response rates were moderate, TMS is a welcome addition to the therapeutic repertoire especially for patients who do not respond to medication.\"\nThe researchers found that 34.6% of the patients being treated by TMS showed a significant response, whereas only 9.1% of patients in the sham group responded ('significant response' was defined as a more than 30% decrease in the Total Auditory Hallucinations Rating Scale score).\nUsing magnetic resonance imaging (MRI), the pulses were targeted at a specific brain area in the temporal lobe, which is associated with language (the exact area is the crossing of the projection of the ascending branch of the left lateral sulcus and the left superior temporal sulcus)\n\nAfter 2 weeks, the patients were re-evaluated.\n\"This is the first controlled trial to precisely determine an anatomically defined brain area where high frequency magnetic pulses can improve the hearing of voices\", said lead researcher, Professor Sonia Dollfus (University of Caen, CHU, France).\nCommenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job here. For example, the release notes that TMS \u201chas been suggested as a possible way of treating the hearing of voices in schizophrenia\u2026.However, there is a lack of controlled trials to show that TMS works effectively with AVH sufferers.\u201d The release also quotes an independent source saying that \u201cThis work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia. To move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\u201d That\u2019s valuable context.\nHowever, there is one point that raises some confusion. The release notes that this study involved 59 patients in all, and that it has been accepted for publication in a forthcoming issue of the journal Schizophrenia Bulletin. However, a search online finds that a very similar study, by at least one of the same researchers (the only one whose name we know), involving 74 patients, was published online in the journal Neurophysiologie Clinique (Clinical Neurophysiology) in June. Is this part of the same study discussed in the release? If not, how does it differ from the study being discussed in the release? If it is the same, why was there a different number of patients?", "answer": 1}, {"article": "Powe is due to present the findings Friday at the annual European Breast Cancer Conference in Barcelona, Spain.\n\"The concept of controlling tumor growth by preventing a stress or inflammatory response is not novel,\" said Dr. Cathie Chung, a medical oncologist and an assistant professor of oncology at the City of Hope National Medical Center in Duarte, Calif.\n\nFor instance, other research has found that women with breast cancer who regularly take aspirin, which is an anti-inflammatory, may have a decreased risk of recurrence.\nFRIDAY, March 26, 2010 (HealthDay News) -- Treatment with blood pressure-lowering drugs known as beta blockers appears to help reduce the spread of breast cancer in women, a team of British and German researchers report.\nIt's not known, she said, whether there is a true association or whether it may be due to chance or another factor.\n\"Beta- blocker drugs compete with stress hormones and bind to the same target receptors [on a cellular level], but unlike stress hormones, do not activate cancer cells,\" said Dr. Des Powe, a senior healthcare research scientist at Queen's Medical Centre, Nottingham University Hospital NHS Trust, in Nottingham, England.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story points out that \u201c[t]he concept of controlling tumor growth by preventing a stress or inflammatory response is not novel.\u201d It was not mentioned, however, that\u00a0this is the first study\u00a0examining\u00a0beta blockers in breast cancer patients.\u00a0 ", "answer": 1}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not comment on the novelty of PET scanning. How long have they been used for this purpose? ", "answer": 0}, {"article": "Nov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nIn a three-year study of more than 1,300 people with knee osteoarthritis, digital X-rays revealed substantially less loss of cartilage in the joint space in those who took strontium ranelate every day compared with people who took a placebo daily.\nAnd nearly 19% of women and 14% of men age 45 and older have joint pain, stiffness, and other symptoms of knee osteoarthritis, according to a large 2007 study.\nThe function of cartilage is to reduce friction in the joints and serve as a \"shock absorber.\"\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Because the story explained that a form of strontium is available as a prescription drug for osteoporosis in several countries and because it is clear that the study in question is about a new use for this medication, we\u2019ll give the story the benefit of the doubt \u2013 even though it could have explained better that the idea that strontium ranelate can be effective for osteoarthritis is not entirely new. In studies of women taking the drug for osteoporosis, the drug seemed to have a beneficial effect on\u00a0markers of cartilage degradation and symptoms of spinal osteoarthritis. Those studies paved the way for the trial being reported on here, but there was no mention of that previous research.", "answer": 1}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story establish the true novelty of the approach?", "explanation": "As the story suggested, these new drugs are the first on the market that are designed to block CGRP in migraine patients.", "answer": 1}, {"article": "Colitis, inflammation of the colon, is the second most common side effect from ICIs, occurring in up to 40 percent of patients, explained Wang.\nThe current data further suggests there is the potential for many molecular studies to better understand the role of the microbiome in driving ICI-colitis and immunotherapy response more broadly.\nThe study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation (FMT) is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.\nPrevious MD Anderson research showed that bacteria in the gut influence patient response to ICI therapy, and other evidence suggests modifying the microbiome in mice can alter their response to immunotherapy.\nThe research, led by Yinghong Wang, M.D., Ph.D., assistant professor of Gastroenterology, Hepatology & Nutrition and director of Medication Induced Colitis and Enteritis, was published today in Nature Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The text maintains that this study represents \u201cthe first time\u201d that fecal transplants have been used to treat individuals with immunotherapy-induced colitis.", "answer": 1}, {"article": "The hypotensive effect was dependent on time.\nMoreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\nThe maximum systolic BP lowering effect of melatonin falls between 3:00 and 8:00 in the morning, the time of the highest risk of heart attacks and strokes.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t make a claim to novelty, but then it shouldn\u2019t as this study doesn\u2019t appear to offer anything new. Melatonin\u2019s main job in the body is to regulate night and day cycles or sleep-wake cycles. Many researchers have explored the\u00a0effects of melatonin supplements, and one 2010 review noted that its use was well established \u201cespecially\u201d for sleep disorders, including those related to aging.\u00a0 Much research has also determined that melatonin reduces night-time blood pressure levels in those with hypertension.", "answer": 0}, {"article": "\"The work by [first author] Price et al.\nWhile previous studies have also suggested that resveratrol may have anti-aging properties, the precise mechanism of resveratrol has been controversial.\nIn 2010, according to news reports, the company, which is owned by GlaxoSmithKline, halted clinical trials of resveratrol, but Sinclair said the company continues to develop improved synthetic molecules.\nTUESDAY, May 1, 2012 (HealthDay News) -- Researchers have found new evidence showing that resveratrol, a compound found in red wine, may play a role in preventing cell aging.\nThe study in rodents found that when mice had a particular gene -- SIRT1 -- knocked out, or turned off, resveratrol had no effect on them.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did mention some previous research on the issue:\n\u00a0 \u201cWhile previous studies have also suggested that resveratrol may have anti-aging properties, the precise mechanism of resveratrol has been controversial. Several studies, including work with yeast, worms and flies, have found that resveratrol acts on a class of seven genes known as sirtuins and, in human cells, SIRT1 in particular.\u201d", "answer": 1}, {"article": "But she said it\u2019s more convenient and less time-consuming to administer.\nThe 10-minute, non\u00adinvasive examination can detect subtle lapses in the brain\u2019s perceptual ability that may signal the early stages of mental decline caused by dementia.\nThe federal government\u2019s approval to market the device comes as Alzheimer\u2019s researchers everywhere step up the pursuit for easier and more inexpensive ways to identify dementia in its earliest stages.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\nThe task becomes more difficult, especially for people with early stages of dementia, as the dots move around, changing their direction, speed and intensity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the device has been approved by the FDA, which counts toward novelty, and it also links to a previous story that discusses other noninvasive exams being tested for early diagnosis of dementia. We\u2019ll award a Satisfactory on that basis, although we think readers might come away from this story thinking that this is the first computerized diagnostic test for the diagnosis of dementia. In reality, there have been multiple attempts at the development of computerized testing including several that are available online.", "answer": 1}, {"article": "(CNN) -- The use of mammograms has dipped since a medical task force made controversial recommendations that women in their 40s may not need to get breast cancer screenings every year, according to one of three small studies to be presented Monday.\n\"It might make women not want to get the test,\" she said.\n\"There is a real, but rather modest benefit.\nBreast cancer ID'd more accurately by docs who see more scans\n\nPlecha's findings were not surprising to Moyer.\nMammograms are less effective in detecting growths in younger women, whose breasts may be denser.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Adequate job putting the new studies in context of past research and recommendations.", "answer": 1}, {"article": "Chicago \u2014 Local bans on artery-clogging trans fats in restaurant foods led to fewer heart attacks and strokes in several New York counties, a new study suggests.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nAdmissions for heart attacks and strokes declined in all counties, going from more than 800 to less than 700 per 100,000 people, but the drop was steeper in counties that enacted bans.\nAlice Lichtenstein, a heart and nutrition specialist at Tufts University\u2019s Boston campus, said the results are encouraging but that other changes could have contributed, such as smoking bans and mandatory calories on menus.\nThey were once commonly used to make restaurant fried chicken, French fries, doughnuts and other foods and found in grocery items including cookies, crackers and margarine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0implied that this study\u2019s finding is not novel, with this quote:\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nBut, we wish the story would have explained this a little more specifically, as Reuters Health did. They mentioned that previous studies looked at mortality from heart disease, and that until this one was published, \u201cno study looked at non-fatal cardiovascular issues like hospitalizations due to heart attacks and strokes, however.\u201d\u00a0", "answer": 1}, {"article": "Experts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nAt the annual Alzheimer\u2019s Association International Conference, researchers say they have found a series of substances in saliva that can distinguish between people who experience normal aging, those with mild cognitive dementia (MCI, which in some cases can lead to Alzheimer\u2019s and in other cases not), and Alzheimer\u2019s disease.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The research discussed here is novel in a general sense, but the story doesn\u2019t establish this to a satisfactory degree. A number of previous studies have looked at saliva markers of Alzheimer\u2019s, and there are probably dozens of other blood tests, scans, and other approaches currently in development to address the diagnosis of Alzheimer\u2019s disease. The story does not allude to this research.", "answer": 0}, {"article": "Federal grants helped pay for the work.\nThe difference could mean 50,000 to 70,000 fewer deaths and 100,000 fewer cases of kidney failure each year in the U.S., researchers estimate.\nSince there are about 30 million people hospitalized in the U.S. alone each year, \u201cthere are tens or hundreds of thousands of patients who would be spared death or severe kidney problems by using balanced fluids instead of saline,\u201d said one study leader, Vanderbilt\u2019s Dr. Matthew Semler.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\n\u201cWe\u2019ve been sounding the alarm for 20 years\u201d about possible harms from saline, said Dr. John Kellum, a critical care specialist at the University of Pittsburgh.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story refers to a 20-year effort to better understand which IV fluids are best to use, which is helpful context. We think the story could have better stressed that\u2019s what\u2019s novel here is the size of the studies\u2013lots of patients were included. But, we\u2019ll give this a satisfactory for at least providing context.", "answer": 1}, {"article": "JACC is ranked No.\nIn addition, as many as 20 percent of people hospitalized with a heart attack report symptoms of depression, while patients with heart disease have three times the risk of developing depression compared to the general population.\nThe College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications.\n\"Our findings highlight the link between worsening depression and cardiovascular risk and support routinely assessing depression in patients to determine heart disease risk.\nThis research also demonstrates the positive effects of exercise for all patients, including those with depressive symptoms,\" said study author Arshed A. Quyyumi, M.D., co-director of the Emory Clinical Cardiovascular Research Institute in Atlanta.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of the research lies in its effort to study how the association between depression and cardiovascular disease is moderated by the presence or lack of regular physical activity. If regular exercise were discovered to be a significant moderator, we could use the level of physical activity to further stratify depressive patients into finer categories of cardiovascular risk. This point is missed by the news release.", "answer": 0}, {"article": "Guille said medical students and residents tend to be high-achieving perfectionists, but that they need to learn \"you can't always be perfect in medicine, you have to figure out how to deal with failure.\"\nAn earlier study of 740 interns found that suicidal thoughts increased almost four-fold during the first three months of residency, said Dr. Constance Guille of the Medical University of South Carolina in Charleston.\nIt often involves 80-hour weeks and overnight hospital shifts dealing with multiple medical crises.\nInterns who got the sessions were 40 percent less likely to have suicidal thoughts during that first year compared to those who received four weekly emails with information about depressions and where to seek help.\nThe study involved interns at Yale University and the University of Southern California.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Web based therapy for depression is not new or novel. \u00a0Its use in general population is well described in the literature. \u00a0What is perhaps new is the use of a web based protocol in this high risk group.", "answer": 0}, {"article": "For more information about our products and organization, visit http://www.\nApril 29, 2016 - A modified surgical technique may provide a simpler approach to the surgical treatment for one type of chronic headache, according to an \"Ideas and Innovations\" paper in the May issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nThe official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.\nIt's unclear why the three remaining patients didn't have good improvement, although Dr. Peled notes that two of the three had had temporal headaches for decades before surgery.\nHe comments, \"This is a straightforward technique and effective procedure that may make it easier for plastic surgeons to adopt and offer surgical options for patients with this debilitating condition.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The Gillies incision is not a new procedure, as it has been in use since 1927. The news release makes this clear, explaining that many surgeons are already familiar with this approach, which is used to repair cheekbone fractures.\nThe news release also points out this paper adds to the \u201calready growing body of research showing good outcomes with surgery for chronic temporal headaches\u201d \u2014 again suggesting that the idea is not completely novel.\nWe feel this is good enough to merit a Satisfactory rating.", "answer": 1}, {"article": "An ancient herbal remedy is getting fresh attention this cold and flu season.\nThe Brennan family in Glen Rock, New Jersey, believes it works..\n\n\"So we give the kids, and we take it ourselves, elderberry every morning right after breakfast,\" Kevin Brennan told CBS News.\n\"There is not enough research about whether [elderberry] works in children and there is also isn't enough information about the proper dose in children,\" Dr. Anna Minta of Johns Hopkins Children's Center told CBS News.\n\"The duration and the severity of how they get sick is much less and they get healthy quicker,\" he said.\nOne small study found an elderberry extract called Sambucol could shorten the duration of flu symptoms after a person gets sick by about 3 days.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story refers to elderberry extract as an ancient herbal remedy, so there\u2019s no attempt to frame this as a new discovery. That being said, the intro claims that elderberry is getting \u201cfresh attention\u201d this cold and flu season. Is that true? We don\u2019t see what \u2014 other than the experience of the\u00a0Brennan family in Glen Rock, New Jersey \u2014\u00a0is new here.", "answer": 0}, {"article": "Frank Ruschitzka, MD, of Zurich University Hospital, tells WebMD that ideas that at first seem \"crazy\" can turn out to be lifesaving.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\nThe new study involved 27 people with heart failure so severe that they were comfortable only at rest, 25 people with less severe heart failure, and 28 healthy people.\n\"We saw two distinct patterns, one of which correlated with heart failure,\" says study leader Vasileios Kechagias, a PhD candidate at the University Hospital Jena.\nThe researchers are now testing more than 1,000 patients and trying to identify the odorous molecules unique to heart failure patients, Kechagias says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story indicates that this would be a novel approach, but not enough evidence or context is presented to establish this. While the specifics may be unique, the concept has been the topic of research since the mid to late 1990s.", "answer": 0}, {"article": "Many smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nSome previous studies have suggested that the earlier detection helps, while other research concluded it may do more harm than good by spotting too many benign growths.\nStill, \"a validated approach that can reduce lung cancer mortality by even 20 percent has the potential to spare very significant numbers of people from the ravages of this disease,\" he said.\nThe scans aren't risk-free: They frequently mistake scar tissue from an old infection or some other benign lump for cancer, leading to unnecessary biopsies or surgery that in turn can cause a collapsed lung, infection or other problems.\nIt is most often diagnosed at advanced stages, and the average five-year survival rate is just 15 percent.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story squeaks by this criterion. It mentions earlier trials that left key questions unresolved, but it does not clearly tell readers what was different about this trial.", "answer": 1}, {"article": "\u201cAnd Amgen\u2019s not a company that likes to price gouge.\u201d\n\nSchmidt said Imlygic\u2019s market potential as a standalone drug is \u201cvery, very modest.\n\u201cThey\u2019re old and easily upset, and I can\u2019t look sick.\u201d\n\nEarlier this month, a new scan revealed shadows that could be signs of melanoma.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\n\u201cI think we\u2019re on the cusp of potentially curing patients\u201d with these viruses and other immune therapies, said Dr. Howard Kaufman, chief surgical officer of the Rutgers Cancer Institute of New Jersey and a lead researcher on Bohlin\u2019s trial.\nIn a trial of 436 patients with the disease, 16 percent of participants who received Imlygic saw their tumors shrink for at least six months, compared with just 2 percent of those who received an older immune-boosting drug.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "One of the main points of the story is that this is the first virus to be approved by the FDA for advanced-stage melanoma. That\u2019s about as novel as you can get!", "answer": 1}, {"article": "The researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\nIt is a powerful message that we can prevent cardiovascular disease by what we eat.\u201d Something worth remembering the next time you\u2019re in the produce aisle.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nThe women who ate more berries also tended to eat healthier overall, consuming more vegetables and fruits than those who didn\u2019t eat as many berries; but when the scientists broke down the women\u2019s diets, they found that the highest consumers of berries even had a lower risk of heart attack compared with women who still ate plenty of fruits and vegetables but fewer berries.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does mention that previous studies have tried to analyze the effects of flavonoids, such as on arterial health. So it just barely makes the grade.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - New findings add to confusion over whether taking aspirin, ibuprofen or related painkillers reduces the risk of developing melanoma.\nAnimal experiments have suggested that the class of painkillers known as nonsteroidal anti-inflammatory drugs (NSAIDs) could play a role in preventing melanoma, but a large 2008 study failed to find any evidence to support this possibility.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\nNow, a smaller study that asked people with melanoma and those without the disease to recall their use of NSAIDs has found that taking these drugs - particularly aspirin - at least once a week for more than 5 years may have offered some protection against the deadly disease.\nFor one, you have to get the comparison right, she noted; there\u2019s always a concern that people without cancer who agree to participate in the study may be more health conscious to begin with, and it\u2019s this that protects them from cancer, not their use of NSAIDs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story gave some historical context:\u00a0 \u201cAnimal experiments have suggested that the class of painkillers known as nonsteroidal anti-inflammatory drugs (NSAIDs) could play a role in preventing melanoma, but a large 2008 study failed to find any evidence to support this possibility.\u201d", "answer": 1}, {"article": "The biggest variable is patients themselves.\nTo accommodate them, implant makers are working to build joints with longer-wearing materials, and surgeons are offering more options like partial knee replacements, hip resurfacing and minimally invasive procedures.\nEven the most fit patients face a long period of rehabilitation after surgery and may not be able to resume high-impact activities.\nStill, there are no long-term data on how any of the latest implants will fare in actual patients.\nFor example, many hips and knees use a combination of metal and polyethylene parts, and continuous motion can wear away small polyethylene particles.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article explained that the indications for joint replacement have been gradually expanding to include younger patients, among whom knee and hip replacement might previously have been a \u201cnovel\u201d procedure.\n\u00a0\n", "answer": 1}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes no false claims for the novelty of Botox treatments for wrinkles. ", "answer": 1}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the RapidArc may be new to the market, the story provided no insight as to how the radiation treatment from this device compares to others on the market. \u00a0Is it delivering something that is truly unique or are there other systems out there that can similarly focus the radiation beam used in treatment? (In fact \u2013 going to the company website, it appears that RapidArc is just a modification of existing intensity-modulated radiation therapy technology. The story says RapidArc is used in conjunction with IMRT and image-guided radiation therapy.\u00a0 But what does that mean?)", "answer": 0}, {"article": "Photophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\nA new study from the University of Cincinnati (UC), published online this week in the Journal of Athletic Training, assessed the use of colored lenses in post-concussion patients and found wearing certain color-tinted sunglasses may be a good alternative to dark sunglasses.\n\"We found that 85 percent of patients reporting photophobia had relief of the symptoms with one or more colors-- blue, green, red and purple--with no reported adverse events,\" Clark says.\n\"The use of the colored glasses in the high school, college or other setting can allow a person to engage in some medically approved activities, while minimizing the risk of symptom exacerbation.\nCINCINNATI--Following a concussion or mild traumatic brain injury (TBI), patients may suffer from light sensitivity or photophobia, making it challenging to return to normal activities.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t tell us if testing different colored lenses on people with concussions is novel research. It does say that researchers found that \u201cwearing certain color-tinted sunglasses may be a good alternative to dark sunglasses.\u201d", "answer": 0}, {"article": "The F.D.A.\nThe other ingredient, sacubitril, inhibits an enzyme known as neprilysin, a new mechanism of action for a heart failure drug.\nTimothy Anderson, pharmaceutical analyst at Sanford C. Bernstein & Company, said in a recent note that Entresto was \u201clikely to become a mega-brand over time\u201d but that the initial uptake was \u201clikely to be on the slower side given the entrenched nature of off-patent ACE inhibitors.\u201d He said it was highly unusual that there were no major competitors for Entresto on the way, giving it a \u201clong runway.\u201d\n\nIn a clinical trial with more than 8,400 participants, patients were randomly assigned to take either Entresto or enalapril, an ACE inhibitor.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\nAfter about 27 months, 21.8 percent of those taking Entresto had either died from cardiovascular causes or had been hospitalized for worsening heart failure, compared with 26.5 percent for those taking enalapril.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "At the very end of the story, it notes that Entresto is made of two drugs \u2014 one of which has a novel \u201cmechanism of action\u201d for a heart failure drug. It doesn\u2019t tell us how or why it\u2019s novel, nor does it explain how that mechanism of action works. That would have been worth exploring. That issue aside, the story is also about the FDA approval of the drug, which is clearly a new and noteworthy event.", "answer": 1}, {"article": "The Johns Hopkins researchers also calculated the effects of surgery on health costs for the patients.\nWhile mortality in the hospital was 0.3 percent, some 21 percent of patients had to be admitted to the hospital again for one reason or another within a year of their operations.\nAfter a $616 increase in expenses during the first year following surgery, the costs declined by $2,179 in the second year and $4,497 in year three.\nThe most common drugs before treatment were metformin, a generic taken by about half of patients, followed by the medicines Avandia and Actos, taken by more than one-third of patients.\nThe ultimate savings case requires some extrapolation, though.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nNot applicable because the story really doesn\u2019t make any claims about the novelty of stomach-reduction surgery. It could have provided readers with background about other studies about the effects of this surgery on diabetes. Even in a short blog story such as this, links could be used to achieve this goal. ", "answer": 2}, {"article": "Adding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\nThis appeared to be due to reduced appetite and food intake.\nThey can see that their unexpected and unpredictable oscillations of blood sugar are minimized.\nHemoglobin A1c levels dropped from 6.5% to a normal level of 6.1%.\nThey also lost weight,\" Dandona tells WebMD.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There\u2019s a good description of how the drug works and why it hasn\u2019t previously been studied in individuals with type 1 diabetes.", "answer": 1}, {"article": "Abstract 375: Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.\n\"This is an exciting way to look to the future, but patients living with advanced liver cancer should understand that this treatment will not be available for several years, except through clinical trials.\"\nThis abstract can be found at sirmeeting.org\n\nThe Society of Interventional Radiology is a nonprofit, professional medical society representing more than 7,500 practicing interventional radiology physicians, trainees, students, scientists and clinical associates, dedicated to improving patient care through the limitless potential of image-guided therapies.\nThe authors note several limitations of the current study, including the preliminary nature of the results, as well as the number of patients tested.\n\"Image-guided treatments have expanded the options available for patients with liver cancer from innovative approaches to biopsies to resections to chemo,\" said Raman.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The lead researcher was quoted saying, \u201cThis minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.\u201d\nThe idea of deploying natural occurring viruses to selectively kill cancer cells has been around for decades but research has taken off in recent years, according to a 2016 paper. It states: \u201cMany clinical trials using T\u2010VEC are currently performed worldwide by the (Amgen) pharmaceutical company in order to expand its application and also to expand countries for marketing.\u201d", "answer": 1}, {"article": "Gonzalez said the new trial addressed a serious medical need.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\n\"This clinical trial moves us significantly closer to preventing strokes and death in high-risk populations,\" said Keith Black, MD, professor and chair of the Department of Neurosurgery.\n\"Even under the best current treatments, ICAD carries high rates of recurrent stroke and death, compared with other causes of stroke,\" he said.\nLOS ANGELES (Embargoed Until Oct. 18, 2018 @ 10:05AM ET) -- A surgical technique called EDAS (encephaloduroarteriosynangiosis) significantly decreases the rate of stroke recurrence and death for patients with severe atherosclerosis of the brain arteries, according to findings of a Phase IIa clinical trial presented today at the World Stroke Congress in Montreal.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release quotes an expert stating that \u201cThis clinical trial moves us significantly closer to preventing strokes and death in high-risk populations.\u201d\u00a0 But is that really the case when the results show lack of statistical significance?\nThis release and potential news coverage of it could lead to false hopes by patients who have had a TIA or stroke\u00a0and are looking for any available therapy to reduce their risk of recurrence.", "answer": 0}, {"article": "What's the point of a runny nose?]\n\u201cIt's almost symbiotic,\u201d Navarro said, \u201cbecause in order for it to survive and thrive, it needs its host to be happy and healthy.\u201d\n\nPerhaps the adaptations that help the parasites stay hidden also benefit their host by reining in overactive immune systems.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nThinking that they might be onto something, the researchers found 12 adults with celiac disease \u2014 a serious genetic disorder that causes an autoimmune response to gluten \u2014 who volunteered to have doctors infect them with a slimy, slithery hookworm.\nThis suggests that AIP-2 might also help humans, since dendritic cells have the same function in us that they do in mice.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Research about therapeutic use of hookworms and other parasitic worms (helminths) has been around since the 1990s, although it has entered into the public consciousness within the past five years at most. So in one sense, the material in this article is novel. The beginning of the story describes the genesis of this line of research in questions about the\u00a0connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease. However, the article makes no mention of multiple previous and ongoing studies investigating the effects of \u201cworm therapy\u201d on auto-immune diseases like Crohn\u2019s disease, multiple sclerosis, and asthma. The idea that parasites may play a role in the development of the human immune system is still surprising for most of us, but not as novel as this report on the findings of a single research group would suggest\u2013just a few months ago we reviewed an NPR story on worms for allergies. The article should have provided more context.\n\u00a0", "answer": 0}, {"article": "Johnston says the fight against obesity needs creative solutions that help people manage their weight, appetite and hunger by offering socially acceptable food choices.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nThis is especially true if a student doesn't have access to other meals during the school day.\n\"We have a lot of kids skipping meals for a whole bunch of reasons,\" he said.\n\"We'd like to think it's preventable, but from where I sit right now, there hasn't been a lot shown to be very effective on a large scale.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make clear what\u2019s novel about the research. Prior to this research it was already widely accepted that choosing healthy snacks (along with physical activity) over unhealthy ones is helpful in preventing weight gain.", "answer": 0}, {"article": "Funding for HAB comes from Hass avocado producers and importers in the United States.\n(See conclusion of study)\n\n\"Interestingly, our results indicate that even healthy subjects with a relatively normal baseline TC (100 to 240 mg/dL), LDL-C (75 to 150 mg/dL), and TG (50 to 175 mg/dL) had significant reductions,\" says Sachin Shah, PharmD, corresponding author and expert in cardiovascular health.\nThe research, \"Impact of avocado-enriched diets on plasma lipoproteins: A meta-analysis,\" conducted at the University of the Pacific and independently funded , looked at 10 unique avocado studies with 229 participants, assessing the impact of avocados on cholesterol levels.\n\"Fresh avocado, as part of a balanced diet, and as a cholesterol-free substitute for solid fats, can help be part of the solution for maintaining normal cholesterol levels,\" says Nikki Ford, PhD, Director of Nutrition, Hass Avocado Board.\nAs we head into American Heart Health Month (February) it's important to remind people that they have the power to help control their risk factors for developing heart disease by exercising regularly, knowing cholesterol levels and keeping them under control and maintaining a healthy weight.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes it clear that the study is an analysis of previous research and that it lends further support to the idea that avocados may be beneficial to one\u2019s diet. It\u2019s evident that the \u201cnews\u201d here is the study, and that the idea that avocados lower cholesterol isn\u2019t novel in and of itself.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the diagnostic method and the treatment were accurately reported.", "answer": 1}, {"article": "Led by John Weeks (johnweeks-integrator.com), the Co-founder and past Executive Director of the Academic Collaborative for Integrative Health, JACM publishes controlled trials, observational studies, scientific reviews and leading commentary intended to help medical organizations and governmental organizations optimize the use of integrative products, practices, and practitioners in patient care and in delivery and payment strategies.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\nIts biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide.\nNew Rochelle, NY, June 19, 2017-A pilot feasibility study to determine if young children with autism spectrum disorder (ASD) and their parents would tolerate and adhere to an office- and home-based acupuncture/acupressure intervention showed completion of all 16 biweekly sessions and measurements of their effects before, during, and after the protocol.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Acupuncture research related to ASD is not new. Here\u2019s a systematic review of the relevant literature from 2011, and another from the same year. The Cochrane review, among the collection of studies included in the reviews above, concludes that: \u201cWe need high quality trials of larger size and longer follow-up as the evidence base at present has many limitations.\u201d\nBut the study described here tackles the subject in a new way, that of the feasibility of being able to complete therapy.\u00a0 Prior studies haven\u2019t shown that it\u2019s feasible for families to commit to longer term acupuncture therapy.", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story immediately states\u00a0that this\u00a0is an experimental therapy and that there are no approved gene therapies currently available in the United States. It would have helped readers to know that over a dozen medical centers across the country are entering their second year of Phase I or II trials with CAR-T.", "answer": 1}, {"article": "For more information, visit http://www.\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nThe underlying mechanism for MDD that the intervention targets involves an imbalance in the activity of specific brain regions: individuals with MDD show hyperactivity of neural systems involved in emotion processing, such as the amygdala, coupled with decreased activity of systems involved in cognitive control and emotion regulation, such as the prefrontal cortex.\nA treatment for depression using Emotional Faces Memory Task (EFMT), a technology originally developed by two Mount Sinai researchers, resulted in a significantly greater reduction of major depressive disorder (MDD) symptoms compared to a control group, according to initial clinical results presented at the Society of Biological Psychiatry Annual Scientific Convention on May 19, 2017, in San Diego.\nErik Lium, PhD, Senior Vice President at MSIP, said, \"We strongly believed in the potential of this technology based on early trials at Mount Sinai, and are pleased with our commercial partnership with Click Therapeutics.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes the\u00a0novelty about this technology. Although we think this could have waited until a large, randomized study had been completed\u2013and peer-reviewed\u2013before they publicized the work.", "answer": 1}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Since AR-V7 is not currently used as a biomarker for treatment of advanced prostate cancer, it is clear enough to the reader that this is a new approach.\nAn important point that is only mentioned in passing\u00a0is that the test is a \u201cliquid biopsy.\u201d Liquid biopsies have\u00a0often been hyped as a revolutionary new approach to diagnosing cancer without invasive procedures. However, due to questions over sensitivity and reliability, they have been controversial and are yet to become commonplace in clinical practice, so readers might have benefited from a little more context on this point.", "answer": 1}, {"article": "MONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nDanish researchers analyzed data from more than 31,000 patients hospitalized with heart attack between 2000 and 2005 and divided the patients into four groups: two groups with heart failure (one that received Plavix and one that did not) and two groups without heart failure (one that received Plavix and one that did not).\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story stated that \"the value of clopidogrel (Plavix) to treat heart failure patients has been long debated.\" ", "answer": 1}, {"article": "MONDAY, July 11, 2011 (HealthDay News) -- Teens who have high levels of folic acid appear to do better in school than those with lower levels, Swedish researchers report.\nIn previous studies, folic acid levels have been linked to mental ability; however, until now this had not been linked with improved school performance, the study authors said.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\nIt's not going to do us any harm and it might do us some good,\" he said.\nIn fact, folate deficiencies may be involved in the development of autism, he added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story discussed story a host of prior studies linking folate to cognitive function and reported that \u201cthese results provide new information\u201d pointing to importance of watching folate status.", "answer": 1}, {"article": "Patel says that makes the impact of the case study \u201cstartling and exciting\u201d because if studies bear the findings out, deep brain stimulation may one day help people with hypertension whose blood pressure remains uncontrolled on multiple medications.\nThat was a surprise because experts had long thought that pain had to be reduced to see a reduction in blood pressure.\nThe case study is published in the Jan. 25 issue of Neurology.\nThough his pain eventually returned after four months, his doctors report that their patient\u2019s previously uncontrolled blood pressure has remained normal for nearly three years.\n\u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain,\u201d says Erlick Pereira, MD, a neurosurgeon at the University of Oxford.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story appropriately characterizes the novelty of the research. It mentions other new surgical approaches to the treatment of hypertension that may also be effective.", "answer": 1}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nThe current treatment is injection with the drug sumatriptan, but frequent use of the drug isn't recommended because of the risk of adverse effects.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\nThe study found that 78 percent of patients reported being pain-free or having adequate relief within 15 minutes of receiving high-flow oxygen, compared with 20 percent of patients after they received high-flow air.\nThis new study included 76 adult patients, aged 18 to 70, with either episodic cluster headache (57) or chronic cluster headache (19).\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a decent job explaining that high-flow oxygen is in scattered clinical use, and that this study provides some validation of a current practice. ", "answer": 1}, {"article": "About UABKnown for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama\u2019s largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are consistently ranked among the nation\u2019s top 50.\n\u201cIt is critical for eye care professionals to have a dialogue with patients who report symptoms because dry eye can be a progressive ocular surface disease.\u201d\n\nThe twice-daily eye drop solution of 5 percent lifitegrast ophthalmic solution is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\nThere is hope for dry eye patients worldwide.\u201d\n\nDiagnosis of dry eye is identified by an eye care professional based on careful evaluation of signs and symptoms, including dryness, discomfort, vision changes and damage to the surface of the eye.\nFocusing her research on all aspects of the eye, Nichols discussed the mechanics of the three layers of the tear film and the importance of each from the cornea outward:\n\u2022 Mucin layer: helps tears adhere to the eye\n\u2022 Aqueous layer or water layer: nourishes and protects the cornea\n\u2022 Lipid or oil layer: lubricates and prevents evaporation and provides smooth refractive surface needed for optimal vision\n\n\u201cWe are unsure which of the 200-plus different lipids and 500-plus unique proteins are most important for protecting and lubricating the eye, and the absence or insufficiency of which results in dry eye,\u201d Nichols said.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims that the product \u201cis the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\u201d That\u2019s partly true, as the fact-checking site PolitiFact might say.\nThere are other prescription and over-the-counter eye drops available for treating the signs and symptoms of dry eye. Restasis, a drug that stimulates tear production, was approved in 2003, so the claim that Xiidra is the first prescription drug \u201capproved in the last 13 years\u201d for dry eye is true, to our knowledge.", "answer": 0}, {"article": "Antioxidants neutralize unstable forms of oxygen called reactive oxygen species that can damage cells throughout the body.\nReactive oxygen species are produced naturally in the body, as byproducts of metabolism; because the brain is an area of high metabolic activity, it is thought to be particularly vulnerable to accumulating oxidative damage over a lifetime.\nResearchers found that among 5,400 Dutch adults age 55 and older, the one-third who reported the highest vitamin E intake from food were 25 percent less likely to develop dementia, including Alzheimer\u2019s disease, over the next decade than the third with the lowest intakes.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\nThe findings, reported in the Archives of Neurology, do not prove that vitamin E itself protects the aging brain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea that vitamin E and other antioxidants might protect against dementia is not new, and the story doesn\u2019t suggest that it is.", "answer": 1}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Examined a new use for a \nclass of medications (statins). ", "answer": 1}, {"article": "\"By wearing the brace, I could get back to sports and was able to call my physician and say 'why didn't we try this first?'\"\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nAnd by and large, they did.\n\"It absolutely gave me almost immediate relief,\" he says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The braces studied were appropriately not portrayed as a new treatment approach.", "answer": 1}, {"article": "The subjects were divided into two groups.\nThe Chrono Solution is designed to deliver the first dose of nicotine replacement therapy (NRT) shortly before a smoker wakes up and then creates a pattern of \"peaks and troughs\" of nicotine delivery throughout the rest of the day to assure the smoker has more nicotine support when cravings are predicted to be strongest.\n\"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging,\" noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors.\nIn fact, most people try 8 to 10 times and this includes quit attempts with standard cessation medications like nicotine patch and gum and prescription drugs like varenicline,\" said Alan Levy, Ph.D., chairman and CEO of Chrono Therapeutics.\nFor example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This device provides nicotine in a novel way by administering it according to Chrono\u2019s \u201cpeaks and troughs\u201d profile and combining nicotine delivery with smartphone app monitoring. The release establishes this but doesn\u2019t overstate things.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe findings suggest a possible intervention for obesity, when combined with healthy eating and exercise.\nThe four people who got the sham stimulation during both visits consumed the same number of calories from the vending machines on each visit and did not lose weight.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\nParticipants then ate and drank as much as they wanted from computerized vending machines.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s clear this is being studied at a federally funded obesity center and that the approach of measuring calorie intake after stimulation is new.", "answer": 1}, {"article": "Researchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\nFor example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We give the story partial credit here. It notes that several of these amino acids have also been associated with diabetes in prior studies. It does not highlight the novelty of the new study, but suggests\u00a0that the\u00a0novelty\u00a0lies in the particular groupings of\u00a0three or\u00a0five amino acids.", "answer": 1}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the novelty of this study is that it introduces a new brain area (the nucleus accumbens rather than the hypothalamus) as having regulatory control over metabolism.", "answer": 1}, {"article": "They wrote up a plan to test what they called \u201csuperselective intra-arterial cerebral infusion\u201d of Avastin in 30 patients with glioblastomas that had recurred after standard treatment.\nThe new technique refines the art of opening the barrier: it uses microcatheters \u2014 fine, highly flexible tubes that are inserted into an artery in the groin and then threaded up into tiny blood vessels nearly anywhere in the brain \u2014 to spray chemotherapy directly onto tumors or areas from which they have been removed.\n\u201cThe early data is very interesting and exciting.\u201d\n\nThe complexity of a study like this goes beyond the science.\nIt consists mainly of cells that line the walls of capillaries in the brain and are so tightly packed that many molecules in the bloodstream cannot slip out between cells to reach the brain tissue itself.\nDespite a beautiful scan, the first patient who was treated died in October, from pneumonia and the spread of glioblastoma to his brainstem.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach to glioblastomas is implicit: The featured patient is only the second to receive the treatment. \nThe story also explains that the studied method of infusion uses an existing drug in a novel way. \n\u00a0", "answer": 1}, {"article": "Botox's manufacturer, Allergan, thinks those older studies are more credible.\nThe FDA didn't do much in response, but since then it has been getting new reports of serious adverse reactions in people receiving Botox, and launched a safety review.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\n\"This is a new pathway, and we need to think about the implications of this,\" says Edgar Salazar-Grueso, chief medical officer of Solstice Neurosciences, which makes Myobloc.\nThat stands in contrast to the findings of earlier studies, which suggested that the neurotoxin is completely broken down at the injection site into innocuous compounds and does not migrate beyond it\u2014or if it does, only into the bloodstream or lymph system.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not provide a clear picture of how long botulinum toxin has been used and why.\u00a0 It was first approved by the FDA in 1989 for the treatment of two ocular conditions. \u00a0It has subsequently been approved for a variety of uses, though the story mentioned only its cosmetic uses. \u00a0", "answer": 0}, {"article": "Could root canal procedures go by the wayside in the not-too-distant future?\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nWhen dental pulp disease and injury happen, a root canal is typically performed to remove the infected tissues, explained Dr. Adam Celiz, Marie Curie Research Fellow at the University of Nottingham.\n\"What we found is a material that can potentially regenerate components of a patients' tooth,\" Celiz told CBS News.\nThey're developing a new treatment strategy that could someday help heal a damaged tooth using the patient's own stem cells.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggests that this research is indeed new. \u00a0This is indeed not the case, stem cells have been studied for dental applications for years. \u00a0A group in Japan has been developing\u00a0a stem cell based therapy for dental caries that\u00a0has progressed in 2013 to animal studies.", "answer": 0}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\n\u201cOur goal is for them to be on the most varied, nutritious diet possible.\u201d\n\nThe trickiest part is avoiding onions and garlic, the dietitians say.\nIt found that 52% of low-FODMAP patients and 41% of patients on a less-restrictive diet reported \u201cadequate relief.\u201d The difference was not statistically significant, says study co-author William Chey, a professor of gastroenterology.\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes the case that the diet is a different approach than the alternatives (medications, probiotics, fiber), but it also makes it clear that this diet has been around for awhile. This is a trend story on this type of eating, rather than a look at a specific study.", "answer": 1}, {"article": "Using alcohol with phentermine may result in an adverse drug reaction.\nLosing five to 10 percent of total body weight is likely to produce health benefits, such as improvements in blood pressure, blood cholesterol, and blood sugars.3\n\nSome side effects of phentermine that have been reported include pulmonary hypertension, valvular heart disease, palpitations, increased heart rate or blood pressure, insomnia, restlessness, dry mouth, diarrhea, constipation and changes in sexual drive.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nIt has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.\nThe possible role of phentermine has not been established, therefore the possibility of an association between heart valve disease and the use of phentermine alone cannot be ruled out.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We\u2019ll give this release the benefit of the doubt for this category. Lomaira isn\u2019t a new drug, this is only a new dosage that may be more effective for some patients and their prescribing physicians.\u00a0 As such, the novelty of this release is minimal at best.", "answer": 1}, {"article": "AMD, the No.\n\"Results suggest a new path forward in our fight against AMD that may even include a strategy to prevent those at risk of the disease from ever developing it,\" said Brian McKay, Ph.D., associate professor, Department of Ophthalmology and Vision Science, University of Arizona.\nThese provocative results were then confirmed in a much larger data set of 87 million patients where similar results were observed and the study expanded to include prevention and delay of \"wet\" AMD, the most devastating form of the disease.\n\"In the end, L-DOPA may not be the drug that ends the disease but the pathway identified is likely to be a key observation as the search for a cure continues.\"\nResearchers have discovered that patients who take the drug L-DOPA are significantly less likely to develop AMD, and if they do get AMD it's at a significantly older age, according to the study published online Nov. 4 in the American Journal of Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The idea that an established drug might be effective against a disease other than what it was intended to treat is novel enough to justify a release touting the findings of an acceptable study.\u00a0And the release makes clear that this study was prompted by earlier studies in mouse models that supported a role for L-DOPA in AMD.", "answer": 1}, {"article": "June 30, 2010 -- A drug used in Europe as emergency contraception may also treat painful uterine fibroids, researchers say.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\nIt is effective for up to five days after unprotected sex.\nThe hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nSurgery is often the only way to treat painful, bleeding fibroids, but surgery too can sometimes compromise fertility.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly describes that this drug is not new, but has previously only been used as an emergency contraceptive in Europe.", "answer": 1}, {"article": "But are they benefiting from acupuncture itself, or just getting a placebo effect?\nThe group receiving conventional back therapy fared even worse than those receiving fake acupuncture: 59 percent of those patients needed extra pain pills.\nBut in this study, the patients in the \u201creal\u201d acupuncture group all received needles inserted in the same way.\nOnly 15 percent of patients in the acupuncture group required extra pain drugs, compared with 34 percent in the sham group.\nWhen the German researchers tracked how much pain medicine the patients used, they detected a noticeable difference between real acupuncture and the sham treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "      \n\n\n \n\n \nThe article stated in the first sentence that acupuncture has a 2000-year history.\n ", "answer": 1}, {"article": "We showed that the islets [cells] can start to work again,\" said Dr. Yong Zhao, an assistant professor in the section of endocrinology, diabetes and metabolism at the University of Illinois at Chicago.\nBoth groups were given stem cell educator therapy.\nThere were no changes in C-peptide in the control group.\nThis was an initial clinical trial designed to test for safety.\nSix had some residual beta cell function and six did not.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear that this treatment is a new approach.", "answer": 1}, {"article": "But it may be too early to call this a cure.\n\u201cThe question for me would be if there is a difference between patients who were treated with [both] immunotherapy [in the form of low doses of peanuts] and probiotics, and those who were treated with just immunotherapy.\u201d\n\nThat may have to wait for another study.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\nMORE: Babies Should Eat Eggs and Peanuts Early to Avoid Food Allergies\n\nIn the follow-up, which tracked the children for four years after they were treated with the combination therapy, 67% of those who got the combination probiotic and peanut therapy were comfortable eating peanuts, compared to only 4% of those who did not get the treatment.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here would appear to be that this is a long-term follow-up to a study that used probiotics in conjunction with oral immunotherapy for peanut allergy. That\u2019s inferred here, rather than stated explicitly, which isn\u2019t necessarily a deal breaker. But after talking about what impact probiotics might have had in the treatment results, the story ultimately tells readers that figuring out what sets this research apart \u201cmay have to wait for another study.\u201d Having to include language like that is likely a sign to steer clear of a headline like this one: \u201cNew Therapy May Cure Kids of Peanut Allergy.\u201d Then again, the new therapy may not.", "answer": 0}, {"article": "Atrial fibrillation also increases the risk for dementia.\nHowever, the findings show that people with atrial fibrillation should start taking blood thinners as soon as possible after their diagnosis and continue to take the drugs, Friberg noted.\nAt the time they joined the study, about half of the participants were taking oral anticoagulants, such as warfarin, Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban) or Xarelto (rivaroxaban).\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\n\"In order to prove this assumption, randomized placebo-controlled trials would be needed, but such studies cannot be done because of ethical reasons,\" researchers Leif Friberg and Marten Rosenqvist, of the Karolinska Institute in Stockholm, said in a journal news release.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it sound like the anticoagulant-dementia risk connection is a brand new discovery. However, the study that\u2019s the basis of the story notes that numerous researchers have already examined this hypothesis and come to conflicting conclusions. The story should have indicated what\u2019s new and different about this study compared to the previous ones, if anything.", "answer": 0}, {"article": "While current surgical options, such as the 'gold standard' surgery, Transurethral Resection of the Prostate (TURP), can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).\nMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.\nMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.\nThis opens the urethra while leaving the prostate intact.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release offers some details on how this system is different from drugs and other surgical type treatments, so this merits a passing grade.", "answer": 1}, {"article": "Those studies are expected to launch later this year, including two at Penn.\n\"There have been a lot of studies looking at different drugs, but researchers have not seen positive results,\" said the study's lead author Evan Alley, MD, PhD, chief of Hematology and Medical Oncology at Penn Presbyterian Hospital.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nThe study evaluated 25 patients with pleural mesothelioma, all of whom were over the age of 18 and had either already been treated with chemotherapy or were unable to receive it.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the study \u201cis the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\u201d We\u2019ll give the benefit of the doubt here since the study may be the first of its kind, but the phase 1b trial set out to show safety, not effectiveness.  ", "answer": 1}, {"article": "Current AIDS drugs, called anti-retrovirals, reduce virus levels in a patients blood to near zero.\nSome 36 million people worldwide are infected with the human deficiency virus (HIV) that causes AIDS, and the majority of them live in sub-Saharan Africa.\nThe device, created by scientists at Imperial College London and the privately-held U.S. firm DNA Electronics, uses a drop of blood to detect HIV, then creates an electrical signal that can be read by a computer, laptop or handheld device.\nAt the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result,\u201d said Graham Cooke, who co-led the research from the Imperial\u2019s department of medicine.\nThe researchers say the technology, although still in the early stages, could allow patients to regularly monitor their virus levels in a similar way to diabetes patients checking their blood sugar levels.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes the exploratory nature of the test and its speed, at least relative to a standard (though unnamed) lab test, hinting at its novelty.", "answer": 1}, {"article": "heart assocIation Mouth-to-mouth not necessary and seen as deterrent\n\nIn a break from decades-old first aid guidelines, the American Heart Association on Monday endorsed \"hands only\" cardio-pulmonary resuscitation - rapid chest compression without mouth-to-mouth resuscitation - to improve the odds for victims of cardiac arrest.\nThe message is, if there is any doubt, provide \"hands only\" CPR.\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nThe bystander who needs to provide those chest compressions is often a loved one of the victim.\nThat hesitation is rooted not only in reluctance to lock lips with a stranger, but by anxiety over how to perform conventional CPR, in which the rescuer breathes into the victim twice after every 30 chest compressions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article points out that CPR has been taught in first-aid classes for more than 40 years.", "answer": 1}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nLooking back, the experience was even better than I was expecting, and I hope to see nanoparticle therapy advance into an option for anyone diagnosed with prostate cancer in the future.\u201d\n\nThe gold nanoparticles were invented by Naomi Halas, the head of Rice University\u2019s Laboratory for Nanophotonics.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\nThe shells seek out and saturate cancerous cells, and their advanced vibrational properties are then harnessed to cause the tumorous tissue to pulse with extreme temperature when light is applied through a laser specifically designed to excite the particles.\n\u201cThis therapy could be life-changing for men diagnosed with prostate cancer and I\u2019m honored to be among the first doctors the U.S. Food and Drug Administration approved to put it to the test,\u201d said Steven Canfield, M.D., chair of the division of urology at McGovern Medical School at UTHealth, who recognized the possibility of the nanoparticles to treat prostate cancer and helped developed the trial to test the theory.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of this technique seems to be its major claim to relevance yet the description of its novelty barely passes muster. For example, we don\u2019t learn if gold nanoparticle research is being done for other types of tumors or other types of conditions.", "answer": 1}, {"article": "\"I'm single, I'm bouncing around, and I'd like the opportunity to have a family, so I just figured, 'Why not?'\nShe's here thanks to eggs her mom froze several years ago.\nBut eggs alone are more delicate and prone to damage.\nSo far, they're fine \u2014 no abnormalities.\nMeanwhile, the early adopters are starting to come back and use their eggs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a decent job of explaining that the technique is experimental.", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story establish the true novelty of the approach?", "explanation": "A quote in the final paragraph\u00a0from Dr. Won, the engineer who is developing the device, points out that \u201cMany, many companies are trying to develop breast cancer screening devices, \u2026\u00a0but this is different because we want it to be portable and simple, so it could be used in\u00a0\u2026 a doctor\u2019s office.\u201d\u00a0\nAfter reading this piece, readers have no way of knowing if this profiled device is the only one under development that is portable, simple, and inexpensive.\nElastography, the method used to identify tissue with different \u201cfeel\u201d has been under investigation for a number of years.\u00a0 Although other devices underdevelopment may be more expensive, the technology is not new or novel and was originally proposed in the 1990\u2019s", "answer": 0}, {"article": "Qi Sun of the Harvard School of Public Health and his colleagues analyzed data collected from 13.984 female nurses participating in the Nurses\u2019 Health Study, an ongoing study examining a variety of health issues.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\nThe findings fit with current federal dietary guidelines, which recommend up to one drink per day for women and just to two drinks per day for men.\nIn a paper published online Tuesday by the journal PLoS Medicine, the researchers found that those who consumed 15 grams or less of alcohol a day, which is the equivalent of one drink of any alcoholic beverage, when they were about 58 years old on average were more likely to have good overall health when they were about 70 years old.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As with the competing WebMD story, the coverage did not really explain what is novel about this research. It shows that the\u00a0potential protective effect of moderate alcohol consumption extends into older age.", "answer": 0}, {"article": "It's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\nOne study found that 18 percent of patients using the patch were headache-free after two hours, compared with 9 percent of those using an inactive placebo.\nThe patch is attached to the upper arm or thigh, and when the patient pushes a button the drug is delivered through the skin.\nCalled Zecuity, the patch contains sumatriptan, one of the most widely prescribed medications for migraines.\nResearch involving 800 patients ultimately led to the approval of Zecuity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This will be the first skin patch available for delivery of migraine medication, so its novelty isn\u2019t in question.", "answer": 1}, {"article": "Newswise \u2014 Anew gastric balloon that can be swallowed like a pill and then filledwhile in the stomach, helped patients lose more than 37 percent oftheir excess weight over four months, according to new researchpresented here at ObesityWeek 2015, the largest international eventfocused on the basic science, clinical application and prevention andtreatment of obesity.\nThe FDA also approved threeweight-loss drugs since 2012.\nThe catheteris then removed, while the balloon remains in the stomach for fourmonths.\nSimilar to othergastric balloons, the most common adverse events reported were nauseaand vomiting.\nvi\n\nTheASMBS is the largest organization for bariatric surgeons in thenation.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The device manufacturer claims to be the first to deliver a gastric balloon via capsule.", "answer": 1}, {"article": "There is also another issue.\nNow Dr. Berry, the M. D. Anderson statistician, and a group of leading cancer researchers have found that the chemotherapy benefits in those clinical trials were concentrated almost exclusively in women whose cancers were impervious to estrogen.\nAnd the recent data indicating that some women can skip chemotherapy are based on an after-the-fact analysis of selected clinical trials.\nAnd while some, including Dr. Winer, predict that the use of chemotherapy will almost certainly decline in the years ahead, for now most doctors are sticking with the current guidelines, waiting for expert advice from national panels on what to do.\nThe study is ethical, said Dr. Larry Norton of Memorial Sloan-Kettering Cancer Center in New York, because the only women whose treatment will be decided at random are those in a kind of gray area, not women for whom chemotherapy would be a clear benefit or clearly unnecessary.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes more tailored (often less) chemotherapy as a newer idea for women who may not benefit as much from more aggressive treatment. This idea is based on recent data regarding the benefit of chemotherapy for tumors fueled by estrogen (ER-positive) and those not fueled by estrogen (ER-negative). ", "answer": 1}, {"article": "The new test \"helps push the envelope further,\" he said.\nThe issue with available troponin testing has been that they must be repeated two more times over the next 12 to 16 hours for accurate readings.\n\"It is very common to have people going to the hospital with chest pain and it could be something important or something not significant,\" she said.\nResearchers led by Dr. Till Keller at the University Heart Center in Hamburg, Germany, compared the new highly sensitive troponin I test with the current test and other blood markers for heart attack among 1,818 people who showed symptoms of a possible heart attack.\nTypically, the doctor orders an electrocardiogram (EKG) to check for problems with the electrical activity of the heart, along with blood work.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the story the benefit of the doubt on this one for trying to establish the relative novelty of this troponin I test but how it is novel or superior \u2013 as already outlined \u2013 is not adequately addressed.", "answer": 1}, {"article": "J&J also said Cosentyx demonstrated quicker effectiveness than Tremfya during the study.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\nWith $2.1 billion in sales in 2017, Cosentyx has become one of the top revenue earners for Novartis and is expected to make up for falling revenue from its blood cancer treatment, Gleevec, whose patent expired two years ago.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\nThat market is expected to double to $21.11 billion by 2022, according to U.S. consultant Grand View Research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are a number of other biologic drugs that treat psoriasis by altering the immune system (this makes sense, because psoriasis is an autoimmune condition), but Tremfya blocks a specific part of the immune system that has not been targeted before. In other words, it is \u201cfirst in class.\u201d The article does not touch on this.", "answer": 0}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\nWith a goal of enrolling 82 patients, those in the trial will be treated with a combination of anti-myeloma agents and immunotherapy that have a proven record of eliminating minimal residual disease, including the drug carfilzomib and the monoclonal antibody daratumumab, agents that are currently only approved to treat patients whose disease has returned.\nThe clinical trial Monoclonal Antibody Sequential Therapy for Deep Remission in Multiple Myeloma, also known as MASTER, utilizes next generation sequencing technology to detect minimal residual disease down to a level of one cancer cell in 100,000 \u2014 or 100- to 1,000-fold more sensitive than traditional methods to evaluate response.\n\u201cI believe for the first time that we have treatments that are effective enough to make it possible to eradicate multiple myeloma definitively in a substantial proportion of patients, along with having the technology to detect that the disease has been targeted and that treatment can be stopped,\u201d said Luciano Costa, M.D., Ph.D., scientist at the UAB Comprehensive Cancer Center, lead of the Hematologic-Malignancy Working Group, and principal investigator of the MASTER study.\nNewswise \u2014 Multiple myeloma is the second most common type of blood cancer in the United States, impacting more than 25,000 people each year and disproportionatly affecting African-American men.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Most readers of this release will get the impression that this trial is unique, when actually several groups are testing the same drug combination. The release highlights the researchers\u2019 plan to use \u201cnext generation sequencing technology to detect minimal residual disease\u201d (MRD) and to use those MRD results to guide treatment. There is much discussion of using MRD to monitor response to therapy but it is certainly not ready for widespread use.\nSome of the other similar trials also track minimal residual disease, though a quick review of trial descriptions on www.ClinicalTrials.gov does not make clear whether this trial is unique in using the MRD test results to guide treatment decisions or whether this feature is important.\nSimilar trials include:\nA Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma\nDaratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma\nSelinexor and Backbone Treatments of Multiple Myeloma Patients\nAggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant\n2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy", "answer": 0}, {"article": "Ulcerative colitis is a chronic inflammatory bowel disease.\nWEDNESDAY, May 3, 2017 (HealthDay News) -- A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis.\nThe first two trials looked at more than 1,100 patients with moderate to severe ulcerative colitis who had failed with conventional treatment or treatment with newer \"tumor necrosis factor antagonist\" drugs, such as Remicade (infliximab).\nHowever, in all of the trials, more patients taking Xeljanz suffered from infections, such as shingles, than those receiving placebo, researchers found.\n\"How it is used in the real world may be different than how it was used in these studies,\" Swaminath said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this would be one of the few \u201cpill-based\u201d biologic treatments for ulcerative colitis, and also that these results indicate a possible new option for people who haven\u2019t seen symptom improvement with other medications.", "answer": 1}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nArticle: \"Classification of Newborn Ear Malformations and their Treatment with the EarWell Infant Ear Correction System\" (doi: 10.1097/PRS.0000000000003150)\n\nFor more than 70 years, Plastic and Reconstructive Surgery\u00ae (http://www. )\nThe official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues\n\nThe American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world.\nFebruary 28, 2017 - For infants with congenital malformations of the ear, a treatment system called EarWell can gently reshape the ear--avoiding the pain and cost of later surgery, reports a study in the March issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nDr. Byrd comments, \"The EarWell system is effective in eliminating or reducing the need for surgery in all but the most severe congenital ear malformations.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that: \u201cWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach\u2013including a standardized approach to treatment and assessment of the results.\u201d That earns it a satisfactory rating here. However, the release would have been much stronger if it had offered some information as to how these study findings related to previous evaluations of the EarWell system. Are they consistent with previous results? And if they diverge from those results, how so?", "answer": 1}, {"article": "You know your cholesterol, your blood pressure ... your heart gene score?\nIf the approach pans out and doctors adopt it, a bad score wouldn't mean that you'd get a disease, just that your genetic makeup increases the chance \u2014 one more piece of information in deciding on care.\n\"There are things you can do to lower the risk,\" Kathiresan said \u2014 the usual advice about diet, exercise, cholesterol medication and not smoking helps.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\nFor example, when the researchers tested the system using a DNA database from Britain, less than 1 percent of people with the lowest risk scores were diagnosed with coronary artery disease, compared with 11 percent of people with the highest risk score.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A genetic test capable of gauging a person\u2019s risk of multiple diseases, based on a test looking for multiple genes, is clearly interesting enough to warrant a story, although the success of the test in actual practice with patients may be far less than the optimistic statements the story allows the researchers to make.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Recommended pneumonia vaccinations in older adults and those with compromised immune and respiratory systems is not new.\u00a0 The story focused on new recommendations that all adult smokers be vaccinated. ", "answer": 1}, {"article": "By the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nThat compared to seven drinks a day for the placebo group.\nAt the start of the study, they drank, on average, 11 standard drinks daily.\nThe drug costs at least $350 a month, plus the price of doctor's visits.\nThe drug, Topamax, works in a different way than three other medications already approved for treating alcoholism.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that this is a new use for a prescription medication currently on the market for other uses.", "answer": 1}, {"article": "\u201cThat\u2019s what\u2019s good about this program.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase.\nAt the fourth month mark, \u201cthe gap was huge\u201d between the texting and control groups, she told Reuters Health in a telephone interview.\nEveryone has different information-seeking behavior\u201d and the system can respond to that, Dr. Wen said.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story lacked context about the increasing use of text messaging for patients support, including during chemotherapy, and it didn\u2019t explain how this system works. Did clinicians answer patients\u2019 texts, or were the answers given by a computer? It\u2019s not clear.", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nCompared with oral medication, he says, \u201cthe odds of success are better with the laser; plus, there\u2019s no side effects.\u201d\n\nThe most common oral treatment, Lamisil, works for about two out of three patients, according to Lamisil\u2019s FDA-approved prescribing information, but it has been associated with rare cases of serious liver problems.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn one small study about laser treatment for toenail fungus, which appeared last year in the Journal of the American Podiatric Medical Association, \u201c26 eligible toes (ten mild, seven moderate, and nine severe)\u201d were treated with a laser produced by Nomir Medical Technologies, which is still seeking FDA approval.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are many claims of success in this story but no proof that the treatment is truly novel or that it truly represents \u201chope.\u201d Lasers have been used off label to treat toe nail funges for several years, as the story notes.", "answer": 0}, {"article": "The simple answer is yes!\n\u2022 3 diet shakes per day and 240 grams of non-starchy vegetables taking in between 600 and 700kcal a day for 8 weeks\n\u2022 volunteers then gradually returned to eating normal food over the next two weeks with very careful instruction on how much to eat\n\u2022 volunteers were seen once a month and supported with an individualized weight maintenance programme over the next 6 months\n\u2022 to keep weight steady after the weight loss, they were eating around one third less than before the study\n\nAllan Tutty, 57, from Sunderland, transformed his health by taking part in the study.\nThe study, published today in Diabetes Care, is the latest research from world-renowned Professor Roy Taylor, Professor of Medicine and Metabolism at Newcastle University, who also works within Newcastle Hospitals.\n\n\u2022 People who have had Type 2 diabetes for up to 10 years can reverse their condition\n\nA new study from Newcastle University has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.\nThe research is part of a growing body of evidence showing that people with Type 2 diabetes who successfully lose weight can reverse their condition because fat is removed from their pancreas, returning insulin production to normal.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The study addresses novelty through this statement: \u201cThe research is part of a growing body of evidence showing that people with Type 2 diabetes who successfully lose weight can reverse their condition because fat is removed from their pancreas, returning insulin production to normal.\u201d We think that\u2019s not quite appropriate positioning of the results. While it\u2019s true that there is considerable evidence from studies of weight loss surgery that diabetes values can be normalized with significant weight loss, this release is also suggesting that it has proven that all diabetes patients can reverse the disease through diet alterations, and that the benefits are due to a reduction in fat in the pancreas. These claims go too far based on the small study size and a demonstrated 40 percent success rate.", "answer": 0}, {"article": "Abraham is a consultant for the company.\nThe research team tested the safety and effectiveness of a transvenous phrenic nerve stimulator made by Respicardia Inc. Much like a pacemaker, it sends a regular signal telling the diaphragm to breathe during sleep.\n\"Not only did we see this reduction in events per hour, the patients also rated themselves better on the Epworth Sleepiness Scale (meaning they were less sleepy during the day) and on a global assessment of their overall quality of life,\" Abraham said.\n\"This tells us the effects of neurostimulation are clinically relevant and this could be a promising therapy for those with central sleep apnea.\"\nUnlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not make any claim of novelty, and that\u2019s unfortunate. The published study did note that the trial was the first of its kind, to the best of knowledge of the researchers. But readers who don\u2019t go beyond the release won\u2019t be privy to this.", "answer": 0}, {"article": "It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\"\n\nMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).\nThey circulate in blood and can be purified in their millions from a single vial of blood.\nExosomes are nano-sized particles shed by almost all cell types in the body and are packed with micro-RNAs and other types of small RNA.\nThey are called miRNA because they are very short, only 18-25 letters long.\nIn inflammatory diseases such as MS, there is a significant increase in circulating exosome concentrations.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The text repeatedly notes that this blood test could become the first definitive diagnostic test for MS.", "answer": 1}, {"article": "For more information or to arrange an interview with Dr. Vuksan, please contact:\nThe review also indicated that barley had similar cholesterol-lowering effects as oats, which is often the go-to grain for health benefits.\n\"The findings are most important for populations at high risk for cardiovascular disease, such as Type 2 diabetics, who have normal levels of LDL cholesterol, but elevated levels of non-HDL or apo B,\" said Dr. Vladimir Vuksan, research scientist and associate director of the Risk Factor Modification Centre of St. Michael's.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\n\"After looking at the evidence, we can also say that barley is comparably effective as oats in reducing overall risk of cardiovascular disease\" said Dr. Vuksan.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We don\u2019t think the release established the novelty of the research in the manner it\u2019s claimed:\n\u201cIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\u201d\nHow could it be the \u201cfirst study\u201d when it is looking at a group of studies? \u00a0Is it the first meta-analysis to examine this question? If so, that should be mentioned.", "answer": 0}, {"article": "The surgery worked.\nIf the stomach pouch has stretched, new sutures are put in place to once again reduce the size of the stomach.\n\"It was the first time in my life that I've ever lost a lot of weight and was able to maintain it.\"\nAfter the surgery, Watson says, patients report feeling fuller and less hungry and they ultimately gain greater control over what they are eating.\nWatson says we don't know for sure, but it's possible the body begins to adapt to those changes, which is why the weight loss is reversed over time.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the story does not make any inappropriate claims about the novelty of the procedure, it does not really address the issue. If the procedure is not new, why is it being written about now?", "answer": 0}, {"article": "An accompanying editorial in Mayo Clinic Proceedings also acknowledges the importance of the study.\n\"The meta-analyses of Alexander and colleagues suggests that omega-3 fatty acid intake may reduce risk of adverse CHD events, especially among people with elevated levels of TGs or LDL-C....omega-3 fatty acid intake of at least 1 gram of EPA+DHA per day, either from seafood or supplementation (as recommended by the American Heart Association), continues to be a reasonable strategy,\" said the authors.\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\n\"The results confirm that increasing omega-3s is a healthy lifestyle intervention that can contribute towards reductions in CHD risk,\" added Adam Ismail, Executive Director of GOED.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There are a ton (to use a technical term) of studies on omega-3 fatty acids and heart disease, including lots (and lots) of meta-analyses (like this one or this one, for example). What sets this meta-analysis apart? The release doesn\u2019t tell us.\nAs noted above under the Why This Matters section, there\u2019s considerable evidence and recent consensus that fish oil doesn\u2019t have much if any effect on cardiovascular disease.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nAmong the three groups, researchers found significant differences in rates of death, complications such as bleeding in the brain (severe intracranial hemorrhage), intestinal problems (necrotizing enterocolitis), lung disease (bronchopulmonary dysplasia) and brain and nervous system impairment.\nAbout the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and population issues; and medical rehabilitation.\nSteroids improve survival and reduce the chances of certain birth defects for extremely premature infants, even if the treatment course is not finished before delivery, according to a study funded by the National Institutes of Health (NIH).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As implied by the news release, the main objective of the research was to look at the varying levels of treatment \u2014 in this case, no, partial and complete antenatal courses. Previously, physicians may have opted to forgo treatment when premature delivery is on the horizon, since an entire treatment course takes at least 48 hours. But according to the release, the new study gives \u201cstrong evidence\u201d that even a partial course can provide some benefit.\nThe release might better have characterized the study as yielding minimally statistically significant results rather than \u201cstrong evidence.\u201d\nBut overall, the news release merits a Satisfactory rating for novelty.", "answer": 1}, {"article": "Oct. 6, 2010 -- An extended-release version of the seizure and pain drug gabapentin may be one step closer to becoming the first approved nonhormonal treatment for menopause -related hot flashes .\n\u201cEstrogen and estrogen-progestin drugs are about 95% effective for treating hot flashes,\u201d he tells WebMD.\nResearchers presented findings from two studies of Serada at the NAMS meeting.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\nUtian is now an independent consultant and was a co-author of one of the studies.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "Experts are still divided as to whether raising HDL levels will actually result in any meaningful improvements in clinical outcomes.\n\"There are a lot of people in the prevention/lipid field that are simultaneously excited and leery,\" said Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.\nAdded Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: \"It's very preliminary but it's important because the last drug out of the barrel of this type was not a success.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\nStill, he added, \"the trial demonstrated safety and it demonstrated a tremendous effect on altering the lipid profile in a good direction.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the story a passing score on this criterion because this class of drugs is indeed new and the story did not exaggerate the novelty. However, the story would have been better if it clearly stated that while no drug in this class has been approved for clinical use, there are other drugs at similar stages of testing.", "answer": 1}, {"article": "June 2, 2010 (San Francisco) -- A quick spray of a new drug may help men who suffer from premature ejaculation last nearly six times longer, new research suggests.\nPremature ejaculation can be devastating for both a man and his partner, triggering anxiety, depression, and relationship problems, says Goldstein, who heard the results presented at the annual meeting of the American Urological Association.\nNonetheless, doctors like Irwin Goldstein, MD, director of San Diego Sexual Medicine at Alvarado Hospital in San Diego, tell WebMD they're excited because this is the first time a drug is being rigorously tested for men with really serious premature ejaculation problems.\nNot all men with premature ejaculation suffer to the same degree as the men in the study, says researcher Ira Sharlip, MD, clinical professor of urology at the University of California, San Francisco.\nA total of 358 of the men gave themselves three quick sprays of PSD502 to the head of the penis five minutes before sex and then wiped it off right before penetration.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that the drug \"contains two common painkillers\" and that \"this is the first time a drug is being rigorously tested for men with really serious premature ejaculation problems.\"", "answer": 1}, {"article": "\u201cThere are areas in the brain that become poorly perfused as you age, and that\u2019s believed to be associated with dementia and poor cognition.\u201d\n\nResearchers from the Translational Science Center looked at how dietary nitrates affected 14 adults aged 70 and older over a four-day period.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\n\u201cThere have been several very high-profile studies showing that drinking beet juice can lower blood pressure, but we wanted to show that drinking beet juice also increases perfusion, or blood flow, to the brain,\u201d Daniel Kim-Shapiro, PhD, director of the Translational Science Center at Wake Forest University, says in a news release.\nAnd nitrites help open blood vessels in the body, increasing blood flow and oxygen to places lacking in oxygen.\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story briefly mentioned something about previous studies of nitrites in widening blood vessels, but then claimed that this study was the first to find nitrites also increase blood flow to the brain.\u00a0 Of course, that\u2019s what it said in the news release.", "answer": 1}, {"article": "Age-related macular degeneration affects upward of 15 million Americans.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\nCedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body.\nIn this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We will give the news release the benefit of the doubt on this criterion. \u00a0But here\u2019s why it\u2019s a coin toss.\nThe release states:\u00a0\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration.\u201d\nThat may be. \u00a0There\u00a0are some ways in which these particular stem cells are novel. \u00a0But other stem cell approaches\u00a0have been developed and in some cases are in in early phase human\u00a0trials or animal tests.\nHowever, since we have already dinged this release in the \u201cAlternatives\u201d criterion above for failing to give that context, we\u2019ll give it the benefit of the doubt here.", "answer": 1}, {"article": "The pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nIf clinical trials are successful, the technology means tens of thousands more people could live without the need for frequent insulin injections, although it will take a few years until the treatment is available.\nThe promising early results have given them the confidence to form a wider consortium with the Scottish Islet Transplant Programme, the University of Edinburgh and the Scottish National Blood Transfusion Service.\nOnly 30-50 people with type 1 diabetes in the UK currently receive an islet transplant each year, owing to a lack of donors and the difficulty of extracting islets from pancreatic tissue.\nIt employs more than 100 people and has government backing through Innovate UK but also gets private funding through partnerships.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes it clear that the novelty would be how many more patients could, in theory, receive the treatment if this idea works once in clinical trials.", "answer": 1}, {"article": "Zarate and his colleagues had previously demonstrated that ketamine shots helped some patients with treatment-resistant unipolar depression, meaning they did not cycle through manic episodes.\nThe problem in bipolar illness and depression, he explains, doesn\u2019t appear to be that a person has too much or too little glutamate; instead, it\u2019s likely that the way their neurons release and take up the chemical is out of whack.\nKetamine could improve treatment of bipolar illness and depression in a variety of ways, Zarate said; for example, as a means to jump-start standard drug treatment, or as an anesthetic before ECT.\nIn the US, research is continuing on the drug, he added, and some physicians are likely trying the drug in their patients with bipolar illness or depression who aren\u2019t helped by standard treatments.\nIt\u2019s also a drug of abuse, at much higher doses than those used in Zarate\u2019s research; while patients in the current study received about 50 milligrams during a 40-minute period, a dose too low to induce anesthesia, recreational users of ketamine, known as \u201cSpecial K,\u201d may take hundreds of milligrams per week.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No inordinate claims of novelty were made.\u00a0 The story mentioned some previous research on the drug.\u00a0 It did not discuss the fact that, if the Boston\u00a0Globe story mentioned above is to be believed, a total of 43 patients have been studied over 10 years in federally funded ketamine research.\u00a0 Nonetheless, we\u2019ll give the story the benefit of the doubt. ", "answer": 1}, {"article": "(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\nThe saliva biomarker may be showing that neurons experienced force and not that a there is a concussion, with which the brain cannot perform its typical functions within a normal range, he said: \"I would hesitate to assign too much potential groundbreaking science.\"\nThe study was funded in part by Quadrant Biosciences, a biotech company that hopes to bring a saliva test for concussion to market in the next 12 to 24 months, Hicks said.\n\"Fortunately, the technology required to measure saliva RNA is already employed in medicine; we use it to check patients for upper respiratory viruses in our hospitals and clinics every day,\" Hicks said.\nDr. Steve Hicks, senior author of the study and an assistant professor of pediatrics at Penn State College of Medicine, said the \"five microRNAs in saliva could predict with approximately 85% accuracy which concussed children would have symptoms one month later.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned earlier, the story quotes the JAMA Pediatrics editorial that accompanied the study as saying that the saliva test \u201crepresents an advance in the science of sport-related concussions.\u201d Thus, the test does appear to be a novel approach.", "answer": 1}, {"article": "The designer of that treatment, Dr. Katherine A.\nThe patient cannot be injected again with the same virus because his immune system is now primed to attack it.\nThe virus has a propensity for making liver cells its target, which is good for the therapy because these cells are the natural producers of Factor IX.\nA serious problem with other delivery viruses is that they insert themselves randomly into chromosomes, sometimes disrupting a gene.\nThe virus homes in on the cells of the liver, and the gene it carries then churns out correct copies of Factor IX.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach \u2013 both for what it apparently achieved \u2013 and for how it builds on past research \u2013 was clear in the story.", "answer": 1}, {"article": "MONDAY, March 21, 2011 (HealthDay News) -- While the majority of morbidly obese patients who undergo gastric banding say they are generally satisfied years later, almost 40 percent are saddled with major complications, while about half have to have their bands removed, a small, new Belgian study reveals.\nSo there's a big variability in treatment effect.\nIt is also been reported that LAGB patients are likely to regain much of their lost weight years down the road.\nIt's just not as good as bypass.\"\nBut all this is not to say that I think we shouldn't be doing bands.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear from the story that the procedure is not new.", "answer": 1}, {"article": "Previous surgical treatment was performed on 31 of 38 knees in the study group and 37 of the 42 knees in the control group.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nThe study group consisted of 38 patients, 10 women and 28 men who were at least 40 years of age and a control group with 42 patients (27 men and 15 women) who were 39 years of age or younger.\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\nSAN DIEGO, CA - Knee pain in active patients over 40 is often difficult to treat but according to researchers presenting their work today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in San Diego utilizing a special kind of allograft may be a step in the right direction.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There are dozens, if not hundreds, of journal articles out there regarding the use of osteochondral allograft transplantation to address knee problems. What sets this one apart? Presumably it is the first to directly compare outcomes between older and younger adults, but the release doesn\u2019t explicitly tell readers that.", "answer": 0}, {"article": "Side effects from antidepressants can include constipation, diarrhea and dizziness.\n\"Primary care clinicians and their patients may not automatically consider alternatives when discussing treatment,\" said Halle Amick, research associate at the RTI International-University of Chapel Hill Evidence-based Practice Center and lead author.\n\"Major depressive disorder is a disabling and prevalent form of depression, experienced by more than 16 percent of U.S. adults during their lifetime,\" said Arlene Bierman, M.D., Director, Center for Evidence and Practice Improvement, at the Agency for Healthcare Research and Quality, which funded the study.\nSuch shared and informed decision making might enhance treatment adherence which is one of the main challenges of treating major depressive disorder,\" said Gerald Gartlehner, M.D., associate director of the RTI-UNC Evidence-based Practice Center, who was the principal investigator of the evidence review, which was also published today by AHRQ.\nThey found that symptom improvement and rate of remission were similar between the two options, whether used alone or in combination with each other.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This meta-analysis research on CBT and antidepressants has been around the block a few times. A similar study involving 16 studies and 1700 patients and with a similar conclusion was published in JAMA Psychiatry in September 2015. Prior to being published in the BMJ, this research was presented at a 2014 neurology conference.", "answer": 0}, {"article": "So what's in blueberries that makes them so good for us?\n\"But nonetheless, for the first time I think we have some evidence that the intake of theses anthocyanins may have a protective effect.\"\n\"We showed for the first time that a regular intake of substances that are naturally present in red-, blue-colored fruits and vegetables can reduce the risk of a heart attack by about 32 percent in young and middle-aged women [ages mid-40s to 60],\" compared with women who ate berries once a month or less, says study author Aedin Cassidy of the University of East Anglia.\n\"Even when we adjusted for things like fat intake, fiber intake, medication use, or body size, and for example, exercise, we still got these strong reductions in risk,\" Cassidy says.\nWomen With A Berry-Snacking Habit May Have Healthier Hearts\n\nWhen it comes to supernutritious foods, the blueberry has long had a health halo floating over it.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does mention some previous studies on anthocyanin, looking at possible effects on blood pressure and anti-inflammatory response. NPR even goes into the history and previous research on blueberries, which has been linked to better brain health and decreased risk for Type II diabetes. Also, Dr. Eckel states, \u201c\u2026for the first time I think we have some evidence that the intake of theses anthocyanins may have a protective effect.\u201d", "answer": 1}, {"article": "The study was presented Monday at the annual meeting of the American College of Cardiology in Orlando, Fla.\n\"The most urgent need for innovative strategies to control blood pressure is in low- and middle-income countries,\" Webster said.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\n\"The triple pill approach is an opportunity to 'leapfrog' over traditional approaches to care and adopt an innovative approach that has been shown to be effective.\"\nAmong those who took the so-called \"triple pill\" for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t explain how this study fits into the body of research on combination blood pressure pills.\nAccording to the news release, lead researcher Ruth Webster, MBBS, of the George Institute for Global Health at the University of New South Wales, described the study as \u201cthe first large trial designed to test the theory that starting treatment with low doses and three drugs could achieve better blood pressure control compared with usual care and that combining these drugs in a single pill would make it easier both for doctors to prescribe treatment and for patients to adhere to it.\u201d", "answer": 0}, {"article": "Two studies were of acupuncture, five were of Chinese herbal medicine, one of Ayurvedic herbal medicine and two of Korean topical \u201cseverance secret\u201d cream.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\n\u201cWe need treatments to address it, and it should be treated with equal seriousness as erectile dysfunction.\u201d\n\nThe prevalence of premature ejaculation is difficult to measure because of the differing definitions of the problem and some men\u2019s reluctance to report it.\nTogether, the two acupuncture studies found that the treatment slightly increased intravaginal ejaculatory latency time (IELT) by about half a minute compared to placebo.\n\u201cTo our knowledge, this is the first systematic review to assess complementary and alternative medicine for premature ejaculation.\u201d\n\nAccording to the International Society for Sexual Medicine, premature ejaculation can be a lifelong problem, and this primary form of the problem is usually defined as ejaculation happening within one minute of initiating vaginal intercourse every time a man has ever had sex.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The study establishes its novelty right up front, saying it is the first systematic review of the alternatives to treat premature ejaculation. Based on a literature search we conducted, this appears to be accurate.", "answer": 1}, {"article": "For more information, visit http://www.\nThe researchers in the study also include, Ran Abuhasira, a BGU Ph.D. candidate working in the Soroka Clinical Research Center, Lihi Bar-Lev Schleider of \"Tikun Olam,\" and Prof. Raphael Mechoulam of Hebrew University.\n\"While older patients represent a large and growing population of medical cannabis users, few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments,\" says Prof. Victor Novack, M.D., a professor of medicine in the BGU Faculty of Health Sciences (FOHS), and head of the Soroka Cannabis Clinical Research Institute.\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\nThis older population represents a growing segment of medical cannabis users, ranging from approximately seven percent to more than 33 percent, depending on the country.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There have been several other studies looking at the safety and efficacy of using medical cannabis in the elderly. A 2014 review of them concluded:\n\u201cAdequately powered trials are needed to assess the efficacy and safety of cannabinoids in older subjects, as the potential symptomatic benefit is especially attractive in this age group.\u201d\nThese other studies are not mentioned in the news release.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear this is an emerging technology that is currently being tested to see how it compares with existing approaches.", "answer": 1}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of the medical device is established in the first sentence. The news release reports DigniCap is the first cooling cap cleared for marketing in the United States to reduce hair loss in female breast cancer patients undergoing chemotherapy.", "answer": 1}, {"article": "Did I feel guilty for potentially contributing to the development of a superbug?\nThe studies also noted that the use of antibiotics must be weighed against the risk of antimicrobial resistance, to which prescriptions for childhood maladies such as ear infections are thought to contribute mightily, and against antibiotics' side effects, which can include diarrhea and eczema.\nCurrent practice guidelines for treating kids' mild middle-ear infections -- or acute otitis media -- call for watchful waiting, to be followed by antibiotics only if symptoms worsen or don't cease.\nBoth of the studies, in contrast to earlier research on which the \"watchful waiting\" approach has been based, are considered well-designed, even if they are on the small side.\nOne of the studies noted that while antibiotics -- specifically, amoxicillin paired with clavulanate -- shortened the duration of symptoms, half the children on placebo eventually got better without the aid of those drugs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As discussed above under the Evidence criterion, the blog fails to adequately describe what is novel about the research and what it means for patients and doctors. The studies\u00a0confirmed existing guidance in the U.S. to treat young children with antibiotics when there is a certain ear infection. It doesn\u2019t contradict current U.S. guidelines, as the story suggests.", "answer": 0}, {"article": "And while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nPeople who have a difficult time staying motivated may find relief by the two-week breaks.\nThe dieters ate enough calories to maintain their weight during the off period.\nOne group of men followed the diet, which reduced calorie consumption by about one-third of their individual needs, for 16 weeks straight.\n\"At that point we see almost zero weight loss,\" she explains of her own research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article explains how this diet differs from some others.", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story reports that this drug appears to work by blocking androgen hormones in a way that other hormone-blocking treatments don\u2019t. However, readers are not told whether there are other similar drugs in development.", "answer": 1}, {"article": "We thought it\u2019s time to see if we could pull all [the literature] together \u2026 to see if there\u2019s enough evidence that the benefits individual people notice can be used to help people with mental illness.\u201d\n\nTheir findings suggest that yoga does in fact have positive effects on mild depression and sleep problems, and it improves the symptoms of psychiatric disorders like schizophrenia and ADHD among patients using medication.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\nDespite all of this, the vast majority of studies looking at the benefits of yoga are all small studies.\nThose studies involved too few participants or produced conflicting results to draw any meaningful conclusions.\nThey found positive effects of the mind-and-body practice for all conditions with the exception of eating disorders and cognition.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not make unsubstantiated claims about the novelty of yoga as a psychiatric treatment.", "answer": 1}, {"article": "LONDON (Reuters) - Taking cholesterol-lowering statin drugs such as Pfizer\u2019s Lipitor and AstraZeneca\u2019s Crestor could help prevent people dying from pneumonia, according to a study by British scientists released on Tuesday.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\nPatients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\nThey then matched each statin user \u2014 who was aged over 40 when first prescribed a statin between 1995 and 2006 \u2014 with up to five non-statin users for comparison.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that a possible\u00a0protective effect of statins against infections has been reported previously. It could have also noted that studies haven\u2019t always supported such a relationship.\u00a0 Once again, the story seemed bent on framing only positive outcomes.\u00a0 Nonetheless, we\u2019ll give the story the benefit of the doubt since \u2013 with this criterion in mind \u2013 it at least established that this isn\u2019t the first research on this topic.", "answer": 1}, {"article": "Researchers then rated them using a well-validated scale that measures aggression and agitation.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\nThe drug is approved for treating pseudobulbar affect, a neurological disorder that involves involuntary crying, laughing and other emotional displays as its main symptom \u2014 not involuntary movement of the facial muscles.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\nDextromethorphan is a cough suppressant commonly found in over-the-counter cough medicines, and quinidine is a drug used to control heart rhythm disorders.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "To our knowledge, this is the first study to examine the efficacy of dextromethorphan-quinidine in patients with Alzheimer\u2019s disease.\u00a0The story notes that \u201cAgitation and aggression are common in Alzheimer\u2019s patients, and there is no known safe and effective treatment.\u201d We think that\u2019s enough to establish novelty.", "answer": 1}, {"article": "SUNDAY, Sept. 19, 2010 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.\nThe researchers found that Spiriva plus an inhaled steroid was more effective than giving a double dose of steroids in improving breathing and controlling asthma for these tough-to-treat patients.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\nThese included: Spiriva plus an inhaled steroid; a double dose of the inhaled steroid; and an inhaled steroid plus Serevent, a long-acting beta agonist that relaxes the muscles in the airway.\nFor more information on asthma, visit the U.S. National Library of Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is specific about Spiriva\u2019s mechanism of action and lack of indication for asthma.", "answer": 1}, {"article": "Dr Singh is working with colleagues from the School of Life Sciences and the School of Chemistry at the University of Lincoln to develop teixobactins into a viable drug.\nWith this new knowledge, synthesised versions of teixobactin can be more easily developed, taking the process from up to 30 hours to just ten minutes for a single coupling step - a significant step towards turning teixobactin into a viable new drug.\nThe development of new antibiotics which can be used as a last resort when other drugs are ineffective is therefore a crucial area of study for healthcare researchers around the world.\nHe explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nIt has been predicted that by 2050 an additional 10 million people will succumb to drug resistant infections each year.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the researchers created versions of the teixobactin antibiotic that can be produced far more quickly and efficiently than the natural form. It also notes that this announcement builds on research done over the past 18 months.", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s fairly clear from the story that the use of medication as a means of reducing the risk of developing hypertension in patients with pre-hypertension but without other conditions is new. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story reported on the results of a study that found that bone mineral density in women\u2019s\u2019 hips had an inverse relation to self reported levels of cola consumption.", "answer": 1}, {"article": "WEDNESDAY, Nov. 30, 2011 (HealthDay News) -- Eating baked or broiled fish as little as once a week may boost brain health and lower the risk for mild cognitive impairment and Alzheimer's disease, new brain scan research suggests.\nThe study authors found that eating baked and broiled fish -- but not fried -- helps to preserve gray matter neurons, strengthening them in areas of the brain deemed critical to memory and cognition.\nWith that information, the authors found that regardless of age, gender, physical activity routines, and/or educational achievement, race or weight, those who ate baked or broiled fish had larger mass in the hippocampus, precuneus, posterior cingulate and orbital frontal cortex regions of their brains.\n\"Those who eat baked or broiled fish had larger brains,\" noted study author Dr. Cyrus Raji, a resident in the department of medicine at the University of Pittsburgh Medical Center, Mercy Hospital.\nThe questionnaires revealed that 163 of the study participants ate fish at least once a week, with most consuming fish between one and four times a week.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A WebMD story, by comparison, said \u201cSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer\u2019s disease\u2026.the new study is the first to establish a direct relationship between fish consumption, brain structure and Alzheimer\u2019s risk.\u201d\nThis story had none of that context.\n ", "answer": 0}, {"article": "\u201cIf you\u2019re a busy surgeon, you have a volume to maintain,\u201d Bollinger says, \u201cand it\u2019s hard to go from doing three a day to one during the learning period.\u201d\n\nChristopher Chen, a surgeon who uses the anterior approach at Alta Bates Summit, adds that most doctors \u201cstill use the posterior approach because it\u2019s the one they were taught.\u201d And, he says, the majority of younger surgeons learn the older approach because established surgeons are typically the ones who staff the residency training programs and demonstrate the method they know best.\nBut with a relatively new procedure, surgeons enter from the front and only stretch the muscles aside, avoiding the cutting and minimizing pain and recovery time.\nAnother obstacle to the widespread use of the newer approach is that if established surgeons want to switch, they face time and cost constraints.\nThe surgery is extensive: As its name suggests, it involves removing the joint \u2014 the damaged bone and cartilage \u2014 and replacing it with prosthetic parts made of metal, plastic or ceramics.\nTypically, surgeons enter the joint from the rear, which requires cutting through muscle and cartilage.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the anterior approach to hip replacement surgery is clear in the story.\u00a0 In other words, not all that new anymore.", "answer": 1}, {"article": "\"We have noticed that the H-FABP level alone makes it possible to confirm that there is no risk of trauma in one third of patients admitted after a shock,\" enthuses Jean-Charles Sanchez.\nThe opposite of the CT Scan, an exam that lasts a long time and cannot be done anywhere,\" he adds.\n\"When a person has an accident in the mountain, few practices can do a CT Scan,\" notes the Geneva researcher.\nToday, the only reliable diagnosis is the CT Scan, which is only available in some hospitals and, in addition to being expensive, exposes patients to radiations.\nIt will display the word \"positive\" or \"negative\" and send the result to the patient's or caregiver's smartphone via Bluetooth.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "At least one other blood test to evaluate concussions has been given the green light to be marketed in the U.S., and that\u2019s not mentioned. HealthNewsReview.org reviewed a news release and a CNN story about that device.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story should have been clearer about what is new here. The headline implies that the newness is driven by the increasing popularity of the anterior surgical approach: \u201cSame-Day Hip Replacement Hip replacement surgery is now an outpatient procedure due to an increasingly popular surgical technique; surgeons promise less pain and faster recovery.\u201d\nBut the surgical approach is not new at all, as the text of the story acknowledges\u2013it\u2019s been around forever and was old even when one of us (orthopedist James Rickert, one of four reviewers on this piece) was a resident in the 1980s. What is new is the same-day discharge, which in turn is driven by new and better pain medications and reimbursement schedules that yield greater profits the shorter the hospital stay. The story didn\u2019t zero in on this.", "answer": 0}, {"article": "TUESDAY, Nov. 15, 2011 (HealthDay News) -- An apple a day won't necessarily keep the doctor away, but three kiwis just might help, at least according to a small study that showed that the brown, fuzzy fruit may lower blood pressure levels.\n\"There is biological plausibility, but I would not go and grab three kiwis a day,\" said Dr. Nehal Mehta, a preventive cardiologist at the Hospital of the University of Pennsylvania in Philadelphia.\nThey are rich in lutein, a potent antioxidant, and this may be what is responsible for their blood pressure-lowering powers, said researchers who were led by Mette Svendsen of Oslo University Hospital in Norway.\nIn addition, the study looked at the whole fruit, not individual nutrients.\nThe new study may just \"put kiwis on the map,\" he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019re not given any context about past research looking at kiwis or lutein for blood pressure. We\u2019re also not sure why lutein was highlighted as the potential active agent, instead of potassium, for which there is solidl understanding of how it lowers blood pressure.\nWhy was the study design set up as apples versus kiwis? No explanation given. Is this based on a research track record?", "answer": 0}, {"article": "TUESDAY, Aug. 16, 2016 (HealthDay News) -- An experimental drug appears to reduce the risk of bone fractures in postmenopausal women with osteoporosis better than a placebo and the currently available drug, a new study finds.\nThere were no differences among the groups in other serious side effects, such as nausea and heart palpations, Miller said.\n\"I am hoping that having a second drug available, that it will help reduce the cost,\" he said.\n\"Everybody is going to want to know if this is inferior or superior to Forteo,\" she said, adding that this is an early study.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not make clear the novelty of abaloparatide, and seems to focus rather on the similarities between it and Forteo.", "answer": 0}, {"article": "Rose Cooper, a microbiologist and honey expert at the University of Wales Institute at Cardiff, remains cautiously optimistic that the increased use of honey dressings will help better information to emerge.\nAt a colleague's suggestion, he began looking into manuka honey, and for the past 25 years he has led the way in this particular aspect of apitherapy, the study of honey as a medicine.\n\"Fortunately, manuka is effective in treating burns as well as boils,\" Molan said cheerfully.\nThe picture has not always been so bright for manuka, or its manufacturers.\n\"Not only did manuka clear up the infections, there were no cross-infections,\" Molan says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly indicates that the idea of using honey for wound healing is not a new one but that manuka honey is new to the market.", "answer": 1}, {"article": "\u201cI've responded great.\nI think the prognosis is going to be good now.\u201d\n\nThe most frequent mutation across all cancers occurs in a gene called p53, which contributes to cells becoming oncogenic when they produce a mutant form of the p53 protein (p53 gene mutations are present in about 50% of malignancies).\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\nIn a subsequent laboratory study, the COH researchers showed that these patients\u2019 immune cells could be reactivated by treatment with a PD1 inhibitor that is a biosimilar to the clinical drug called pembrolizumab.\n\u201cWe have two drugs here so it\u2019s hard to dissect which drug did what, but we do think the vaccine played a key role.\u201d\n\n\u201cIt was shocking to me,\u201d said Diamond.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes the p53 vaccine has been used in clinical trials since 2010. The release isn\u2019t claiming that the vaccine is brand new and has never been studied before. The\u00a0new information reported in the release is that one patient apparently responded favorably to the treatment, at least in the short-term.", "answer": 1}, {"article": "Laboratories can use commercially available tests or develop their own.\nThe fact that this uncertainty is occurring so long after the 1998 approval of Herceptin \u2014 the paragon of \u201cpersonalized medicine\u201d \u2014 suggests that it will not be so easy to tailor other drugs to patients based on gene or protein tests.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\n\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nBoth studies reanalyzed tumor samples from earlier clinical trials showing that Herceptin, if used after a tumor is removed by surgery, cuts the risk of the cancer\u2019s recurring by half.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The focus of the story is new (unpublished) data from The American Society of Clinical Oncology meeting suggesting inconsistencies in the determination of Her2/neu status. Tumor profiling has been hailed as a new era in individualized breast cancer treatment, but recent reports from ASCO demonstrate the imperfect nature of the current science, either in the ability to consistently provide accurate results, or in the validity of the assumptions made in the tightness of the linkage between diagnostics, drugs and effectiveness. ", "answer": 1}, {"article": "But there\u2019s a problem with a low-FODMAP diet.\nIt\u2019s what gives bread its elasticity, but it also sets off the immune system of people with celiac disease, damaging the small intestine and sometimes producing painful and unpleasant symptoms.\nGluten is not a carbohydrate; it\u2019s a mix of proteins found in wheat and its close relatives (including spelt, kamut and farro), as well as in barley and rye.\nInstead, it\u2019s fermentable oligosaccharides, disaccharides, monosaccharides and polyols, or FODMAPS.\nThey may assume that they have gluten sensitivity, but some researchers believe that it\u2019s not the gluten they\u2019re sensitive to.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The research referenced in the article was published in 2013, so it is not new. \u00a0The concept of non-celiac gluten sensitivity is not new either. So, exactly what is new that caused the article to be written?", "answer": 0}, {"article": "The median survival of those getting surgery and Hipec, plus intravenous chemotherapy, was 22.3 months, almost double the 12.6 months for those getting only the intravenous chemotherapy.\nOne lost much of her abdominal wall to infection and just died in misery.\u201d\n\nAnother risk is that the surgery may be done unnecessarily.\nBut Dr. Alan Venook, a colon cancer specialist at the , said that a couple of patients referred by him had \u201cdied miserable deaths.\nThe is looking at it, according to people in the field.\n\u201cI\u2019ve had to say my goodbyes to everybody,\u201d Mr. S. said the day before the operation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The growing use of the approach was clear in the story. And the fact that one randomized trial was done fully a decade ago.", "answer": 1}, {"article": "The pill is his blood pressure medication.\n\"When you get to be my age, you're going to be very grateful that you controlled your blood pressure and exercised,\" he says.\n\"With every pulse of your heart, you are pushing blood into these very small blood vessels in the brain,\" he says.\n\"Only about 50 percent of people who have hypertension are actually treated,\" he says.\nIf people knew about the link between dementia and high blood pressure, they might be more inclined to do something about it, Koroshetz says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the news \u201chook\u201d is new research to be presented at the Alzheimer\u2019s Association meeting. (Why not wait for that, to make this story meatier?)", "answer": 1}, {"article": "The alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nIn the newly published study, they set out to determine if the alternative treatment would do the same in women whose symptoms were related to menopause.\nThe women were also given a recording of the hypnotic induction, and they were asked to practice self-hypnosis at home daily.\nThey are linked to declining estrogen levels, but it remains unclear just why the sudden lack of estrogen sends the body into thermal mayhem, and why some women are more affected than others.\n\u201cThere is certainly a need for non-pharmacologic treatments for hot flashes and night sweats,\u201d says North American Menopause Society (NAMS) Executive Director Margery Gass, MD.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that researchers conducted a similar trial in breast cancer patients with treatment-related symptoms. Researchers now wanted to see whether a similar approach could help women whose symptoms were related to menopause. That was good context.", "answer": 1}, {"article": "He points to a recent meta-analysis published in the journal Addiction that concluded that naltrexone helped reduce heavy drinking and cravings for alcohol.\nAs as long ago as 1997, a published study showed that treatment of alcohol dependence with naltrexone by primary care doctors can be effective; follow-up research has confirmed that the primary care approach not only works, but makes treatment much more accessible.\nThe drug seems to curb the euphoric and sedative effects of opiates in the brain.\nBut there's good evidence that the combination of counseling and drugs such as naltrexone can help people cut back on drinking, or move toward abstinence.\nAccording to the NIAAA, \"patients can now receive effective alcohol treatment from their primary care doctors or mental health practitioners by combining the newer medications with a series of brief office visits for support.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this drug has been around a long time, and what\u2019s\u00a0novel here is a recent analysis showing that it is underutilized.", "answer": 1}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article states that cethromycin works by a mechanism that is different from current antibiotics. It would have been useful to describe this mechanism. ", "answer": 1}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was about one more drug-eluting stent that may come on the market but it was unclear about how this stent differs from those currently on the market.", "answer": 0}, {"article": "The Site is down for maintenance.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The drug was described as \u201cnew\u201d but we weren\u2019t told how or why it\u2019s new or how it acts differently than other drugs.\u00a0 No context of other research in this field.", "answer": 0}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nThe researchers found that on average, people treated with acupuncture reported a \u201cmodest\u201d improvement in symptoms compared to those who had sham treatment, and a larger effect compared to untreated patients.\n\u201cThis provides evidence that they would be justified in considering\u2026 acupuncture,\u201d he told Reuters Health.\nThose trials included close to 18,000 patients in the United States and Europe with back and neck pain, shoulder pain, chronic headaches or joint pain due to osteoarthritis.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There have been plenty of systematic reviews of acupuncture that have reported inconsistent findings. (The review referenced above found 57 systematic reviews of the acupuncture evidence.) The story does not\u00a0mention this previous research.", "answer": 0}, {"article": "This diet excludes many compounds found in wheat, certain fruits and vegetables, garlic, onions and sugar substitutes.\nMeanwhile, we strongly recommend that IBS patients work with their physician and a registered dietitian to navigate the Low-FODMAP diet to take control of their IBS symptoms.\u201d\n\nEswaran received funding to conduct the research from the University of Michigan Nutritional and Obesity Center and Prometheus Diagnostics.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nMany practitioners and patients have turned to diet as a possible treatment, but many of the dietary recommendations have not been backed by clinical trials.The study, the largest of its kind, measured the degree of relief from low FODMAP, a frequently recommended diet, which stands for Fermentable Oligo-Di-Monosaccharides and Polyols.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states that the low FODMAP diet isn\u2019t new. But it also states that the study is the \u201cfirst of its kind,\u201d \u201cthe largest of its kind,\u201d and that this is the first time the FODMAP diet has been studied in the United States.", "answer": 1}, {"article": "Comparing states with and without medical marijuana laws\n\nIn order to evaluate whether medical marijuana could function as an effective and safe alternative to opioids, the two teams of researchers looked at whether opioid prescriptions were lower in states that had active medical cannabis laws and whether those states that enacted these laws during the study period saw reductions in opioid prescriptions.\n\"No one has ever died of cannabis, so it has many safety advantages over opiates,\" Bradford said.\nThe first state in the United States to legalize marijuana for medicinal use was California, in 1996.\nBut unlike opioids, marijuana has little addiction potential, and virtually no deaths from marijuana overdose have been reported in the United States, according to Bradford.\n\"We need to study the effects of these policies, and we really haven't done it to the degree that we should.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that marijuana has been shown to be effective in treating chronic pain, and noted that more research is needed on its medical benefits.", "answer": 1}, {"article": "New research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\nThe results have particular relevance for the University of Maryland School of Medicine; this fall the school will open the Maryland Proton Treatment Center (MPTC).\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\n\"This evidence underscores the precision of proton therapy, and how it can really make a difference in cancer patients' lives,\" said Dr. Chuong.\nOthers include:\n\u2022 Selective Internal Radiation Therapy, a precision modality for treating patients with particularly difficult-to-remove tumors involving the liver such as those from colorectal cancers;\n\u2022 Thermal Therapies, the use of \"heat\" in treating a broad spectrum of malignancies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Proton therapy has garnered widespread attention for years because it is reported to cause fewer side effects than other treatments. This study was looking specifically at side effects of proton therapy\u2019s use when treating esophageal cancer, which may be a novel application for the technology. However, the story doesn\u2019t make that sufficiently clear. Is this the first time that researchers have analyzed the effects of proton beam therapy on esophageal cancer? Or is it adding to a body of research on this condition? The story could have earned a Satisfactory rating by clarifying that point.", "answer": 0}, {"article": "CHICAGO (Reuters) - The hallucinogen psilocybin \u2014 known by the street name magic mushrooms \u2014 may help ease the anxiety that often accompanies late-stage cancer, U.S. researchers said on Monday.\nEverything had to be shut down,\u201d Grob said in a telephone interview.\n\u201cIt was something of a public health crisis.\n\u201cForty to 45 years ago, the culture was going through tremendous upheaval.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "The official suggested that the baby might be \u201cwhat a baby girl looks like on the outside,\u201d but that \u201cwe\u2019re giving you the results on the inside.\u201d\n\nMs. Lewis, who sued Acu-Gen, said she ultimately received a refund.\nThe new study found that to be reliable, the sex-determination tests had to be performed after at least seven weeks of gestation.\nIn 2005, she was told she was having a boy, and she chose a name, bought boy clothes and told everyone.\nThese tests analyze hormones in women\u2019s urine, a method that several experts said has not been studied as rigorously as DNA.\nWhile sex selection is not considered a widespread objective in the United States, companies say that occasionally customers expressed that interest, and have been denied the test.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The new research was on testing that is not novel, but by surveying 57 other studies, they reached a new conclusion about overall accuracy and how early in pregnancy it could predict gender.", "answer": 1}, {"article": "Szostak said his role at Elysium Health is to scour scientific literature for new natural compounds that are shown to improve health and bring them to the company\u2019s attention as potential ingredients in new products.\nMost of them have no scientific basis, and you don\u2019t know what you are getting.\u201d\n\nGuarente was involved in several other efforts to develop antiaging medicines that did not pan out.\n\u201cIt is not quite clear to me what they want to target with this pill,\u201d said Pere Puigserver, a biology professor at Harvard Medical School.\nBoth substances are available individually as dietary supplements.\nMany products in the supplement business are launched with questionable science, but Elysium said studies in mice show a clear connection between increased levels of this compound, called NAD, and improved health in older mice.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides excellent context for this product. It explains that the active ingredients are sold separately, but this is the first time this particular compound has been produced.", "answer": 1}, {"article": "The results were just published online by the medical journal The Lancet.\nA study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nSome 14.5 percent of patients who got the drug were dead within a month of being injured compared with 16 percent of those who got the dummy medicine.\nIt works by keeping the body from breaking down clots.\nThe drug is used to reduce bleeding during surgery and is also approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that TXA is already used to control bleeding during surgery and doesn\u2019t portray the treatment as new.", "answer": 1}, {"article": "More than half of patients ultimately die specifically from progressive lung cancer with observation, and 2-year survival is less than 40 percent with either approach,\" write researcher Robert Timmerman, MD, of the University of Texas Southwestern Medical Center, Dallas, and colleagues in the Journal of the American Medical Association.\nThis type of radiation therapy has not yet been approved by the FDA as a lung cancer treatment, but this study brings it one step closer.\nIn these situations, the lung cancer tumor is deemed inoperable and conventional radiation therapy or observation without cancer treatment is offered.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\nThree years after the treatment, the study showed that 28 participants had a complete response to the therapy and 21 had a partial response.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While radiation is not a new idea, stereotactic body radiation therapy is relatively new and has not been evaluated in lung cancer.", "answer": 1}, {"article": "When it's functioning properly, BRCA actually helps repair damaged DNA and prevents tumors, but when BRCA1 and BRCA2 go awry, they encourage breast cancers.\nThe trial results are preliminary, as talazoparib has not yet been approved by the U.S. Food and Drug Administration.\nThe drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing cancer cells from killing healthy ones.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\nIn the current trial, the women who were randomly selected to receive talazoparib had a higher response rate to treatment than women who received standard chemotherapy: 63 percent versus 27 percent, the researchers found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t articulate what\u2019s new about this finding \u2014 except the drug used. With another similar drug already on the market, what might this new drug offer? Is there an unmet need?", "answer": 0}, {"article": "The Food and Drug Administration approved a new drug on Tuesday to treat serious cases of eczema.\n\u201cScratching leads to swelling, cracking, weeping clear fluid, and finally, coarsening and thickening of the skin.\u201d\n\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n\u201cThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u201d the FDA notes.\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story alludes to distinguishing features of the drug and notes that the FDA \u201cgave it both priority review and breakthrough therapy status, speeding it through the approval process.\u201d\nIt could have done a better job of explaining how many people are likely to benefit, other than the 300,000 the manufacturers describe as \u201cmost in need of treatment options.\u201d", "answer": 1}, {"article": "A biotech company today will begin offering the first genetic test to assess a woman's risk for the most common forms of breast cancer, reigniting debate about the growing number of unregulated genetic tests.\n\"There is at least a significant chance this test will could falsely reassure some women and alarm others,\" said Eric Winer, a breast cancer expert at Harvard Medical School and a spokesman for the American Society of Clinical Oncology.\nI certainly wouldn't want my daughter to have such a test,\" said Mary-Claire King, a geneticist and breast cancer expert at the University of Washington.\nThe test by Decode Genetics of Reykjavik, Iceland, a respected pioneer in genetic research, promises to determine a woman's risk through a simple blood sample or cheek swab.\n\"What this does for women is allow them to assess their personal risk for the common forms of breast cancer,\" said K\u00e1ri Stef\u00e1nsson, Decode's chief executive.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that there are other genetic tests, but this is one of the first for breast cancer for women who do not carry the BRCA1/2 gene. The story does not mention that there are several other risk calculators to estimate a women\u2019s risk. ", "answer": 1}, {"article": "Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodriguez Jr. T, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, DeVore B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Davila-Roman V and Eby CS for the GIFT investigators.\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\nPatients in the trial were randomly assigned to one of two groups.\nOne group received warfarin dosing based on standard factors such as age, height and weight; the second group was dosed based on these clinical factors plus genetic variants.\nVariants in one gene affect vitamin K recycling.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release describes how the genetic test used in the new study differs from previous similar studies.", "answer": 1}, {"article": "What if you could lose weight and reduce your risk of life-threatening disease without any changes in what you eat -- other than a five-day special diet once every few months?\n\"This study provides evidence that people can experience significant health benefits through a periodic, fasting-mimicking diet that is designed to act on the aging process,\" said Valter Longo, director of the USC Longevity Institute and a professor of biological sciences for USC Davis and Dornsife.\nTheir systolic blood pressure, which was in the normal range when the study began, dropped by 4.5 mmHG, while their diastolic blood pressure dropped by 3.1 mmHg.\nIn effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\nThe diet, which was designed to mimic the results of a water-only fast, allowed for participants to consume between 750 and 1,100 calories per day.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that this is the \u201cfirst randomized clinical trial with enough participants to demonstrate that the diet is feasible, effective and safe for humans.\u201d\nThe diet being tested is named by the researchers as a \u201cfast-mimicking diet\u201d or FMD.\nWhile this may be the first test of a \u201cfast-mimicking diet\u201d reliant on the ProLon diet kit, the concept of very low-calorie diets is not new and there are hundreds of clinical trials that have delved into reducing risk for cardiovascular disease via diet. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) discusses very low-calorie diets on its web page.", "answer": 0}, {"article": "Scientists are inching closer to a drug that may protect peanut allergy sufferers from potentially life-threatening complications that can occur due to accidental consumption.\nIn addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\n\nEXPERTS: CHILDREN AT RISK OF LEAD POISONING IN CHATTANOOGA\n\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies.\nWhile the drug is not being hailed as a cure for peanut allergy, it has proven successful in building up patients\u2019 tolerance to peanuts over time, lessening the potential for life-threatening complications.\n\u201cWe\u2019re excited about the potential to help children and adolescents with peanut allergy protect themselves against accidentally eating a food with peanut in it,\u201d said allergist Stephen Tilles, MD, ACAAI former president, study co-author and consulting advisor for Aimmune Therapeutics, according to EurekAlert.\n\u201cThis is not a quick fix, and it doesn\u2019t mean people with peanut allergy will be able to eat peanuts whenever they want,\u201d Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author, said, according to EurekAlert.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that the treatment would be a new one, making clear that no other approved product exists for treating peanut allergy.\u00a0\nIt could have added that immunotherapy \u2014 or exposing allergy patients to small, controlled doses of the food they\u2019re allergic to \u2014 is not a new idea.", "answer": 1}, {"article": "Among the most dispensed: eat a healthy diet, keep a healthy weight, avoid alcohol and tobacco and stay away from certain medications, such as blood pressure and depression drugs.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\n\u201cThis fits reasonably well with what we thought about the effects of exercise,\u201d says Dr. Peter Schlegel, vice president of the American Society of Reproductive Medicine and chairman of urology at New York Presbyterian/Weill Cornell Medical Center.\nWhile it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\nIn the study, Behzad Maleki at Justus-Liebig University in Germany and his colleagues recruited 280 sedentary, middle-aged men and randomly assigned them to one of three exercise regimens, or to no exercise, and followed them for six months.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty is established via this quote:\n\u201cThis fits reasonably well with what we thought about the effects of exercise,\u201d says Dr. Peter Schlegel, vice president of the American Society of Reproductive Medicine and chairman of urology at New York Presbyterian/Weill Cornell Medical Center. \u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.", "answer": 1}, {"article": "Says Likosky: \"If you cool the brain down, it may be that it uses less energy and (is) less likely to damage itself over that first 24 hours.\"\nThe idea is that cooling a comatose patient after a heart attack prevents brain damage.\nWe keep them at that temperature for the first 24 hours, at which time we re-warm them,\" Likosky explains.\nResearch has shown it can improve the survival rate by 14 percent.\nIn medicine, in general, we have many very expensive treatments that may make a marginal difference \u2014 treatments that are potentially painful, that cost a lot,\" Likosky says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is relatively clear that hypothermia for management of individuals who have recently had a heart attack is not new.\n\u00a0", "answer": 1}, {"article": "And you could see that they were sort of asking, 'Why can't they do something for me?'\"\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\nIt's not something that a layman like me should be in, it should be left to doctors and research people,\" he told Stahl.\nHere's how it works: one box sends radio waves over to the other, creating enough energy to activate gas in a fluorescent light.\nHis wife Marianne woke up that night to a lot of banging and clamoring.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment implies the technique is a breakthrough and entirely novel. This is not true. The technique is a combination of three treatment approaches familiar to cancer researchers: \nThe segment should have mentioned these things. \u00a0", "answer": 0}, {"article": "The participants were matched with nine patients within the same age bracket who took standard insulin treatment and 23 healthy non-diabetic people aged 20-64.\nHowever, for the first time, a clinical trial has revealed metformin can promote a patient's ability to repair their own damaged blood vessels by increasing vascular stem cells.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\nThe 31-year-old, of Gateshead, was diagnosed with Type 1 diabetes at the age of just seven and has good control of her condition.\n\"Metformin could routinely be used by patients with Type 1 diabetes to help lower their chances of developing heart disease, by increasing a repair mechanism created by vascular stem cells released from the bone marrow.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Since cardiovascular disease is a major risk for diabetic patients, research indicating that an existing (presumably inexpensive) drug may lower that risk clearly qualifies as significant enough to warrant a release, in spite of the fact that this was only a small, limited pilot study.", "answer": 1}, {"article": "Whoopi Goldberg recently stepped in with a new line of medical marijuana\u2013based edibles and bath products (of questionable effectiveness) aimed at this underserved market.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\nBut there's some reason for optimism: The device is basically a repackaging of another (cheaper) technology that has already been proven to help women who suffer with their monthly cycles.\nIn an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nWhen the frequency from the device hits the brain faster than the pain, the brain takes that signal first and is distracted from the menstrual aches, the company claims.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the Livia device has as yet to be characterized fully by the company, but at face value appears to be equivalent to a TENS unit, which have been used for menstrual pain for many years.", "answer": 1}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nIn some cases, studies have found that people who use products like nicotine patches and gums are more likely to relapse than their counterparts who go cold turkey.\nAmong 787 adults who had quit smoking within the previous two years, nearly a third reported having returned to using cigarettes, according to a study published online Monday by the journal Tobacco Control.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There were no claims of novelty in the story.", "answer": 2}, {"article": "Her team of 12, including study co-author and U of A post-doctoral fellow Hein Min Tun, take the science one step closer to understanding the connection by identifying that exposure to pets in the womb or up to three months after birth increases the abundance of two bacteria, Ruminococcus and Oscillospira, which have been linked with reduced childhood allergies and obesity, respectively.\nIn other words, even if the dog had been given away for adoption just before the woman gave birth, the healthy microbiome exchange could still take place.\nThe study also showed that the immunity-boosting exchange occurred even in three birth scenarios known for reducing immunity, as shown in Kozyrskyj's previous work: C-section versus vaginal delivery, antibiotics during birth and lack of breastfeeding.\nThe study, funded by the Canadian Institutes of Health Research and the Allergy, Genes and Environment Network (AllerGen NCE), was published in the journal Microbiome, along with an editorial in Nature.\n\"It's not far-fetched that the pharmaceutical industry will try to create a supplement of these microbiomes, much like was done with probiotics,\" she said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t claim a novel intervention but does say that this research builds on existing research and increases understanding of the pet-allergy connection. We\u2019ll give them the benefit of the doubt on that.", "answer": 1}, {"article": "[2] This number is expected to double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050.\nProfessor Hilkka Soininen, Professor in Neurology MD, PhD from the University of Eastern Finland, who headed the clinical trial as part of the LipiDiDiet project, said: \"Today's results are extremely valuable as they bring us closer to understanding the impact of nutritional interventions on very early AD (pre-dementia) which we are now better at diagnosing but unable to treat due to a lack of approved pharmaceutical options.\nThe clinical trial, headed by Professor Hilkka Soininen is part of a large EC project (LipiDiDiet) to explore the therapeutic and preventative impact of nutrition on neuronal and cognitive performance in ageing, AD and vascular dementia.\nSecondary outcome parameters were brain volumes (total hippocampal, whole-brain & ventricular volumes), the Clinical Dementia Rating Sum of Boxes (CDR-SB), Neuropsychological Test Battery composite scores: episodic memory, executive function/working memory composite and a complete composite score consisting of 16 subtests, progression to (AD) dementia, blood and CSF biomarkers, tolerance and safety.\nIn addition, earlier randomised controlled trials (RCTs) with the product have shown an improved memory performance in drug-na\u00efve mild AD patients, along with a good safety profile.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims novelty with this statement:\u00a0 \u201cThis is the first time a randomised, double-blind, clinical trial has shown that a nutritional intervention can help to conserve the ability of patients with very early AD (pre-dementia) to carry out everyday tasks, such as paying bills, or finding your way around, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) \u2013 a combined measure for the ability to think and perform everyday tasks.\u201d While a nutrition drink to improve memory in people with early Alzheimer\u2019s disease would certainly be a novel addition to the treatment tool chest, we think the novelty boat already sailed three years ago when there was significant coverage of the three previous double-blind studies.", "answer": 0}, {"article": "It appears to be that fasting is causing some major stress, and the body responds to that by some protective mechanisms that potentially have a beneficial long-term effect on risk of chronic disease.\u201d\n\nDr. Horne noted that patients shouldn\u2019t take up fasting without discussing it first with their doctor.\nThe patients were asked if they engaged in regular fasting, and the researchers compared the answers to whether they eventually received a diagnosis of heart disease.\nFor that research, also presented at the New Orleans conference, 30 patients were asked to fast for 24 hours with water only.\nThe scientists used blood tests before and after the fasting period to look at a number of different metabolic markers.\nThe hormone is released by the body in times of starvation to protect lean muscle mass and trigger the body to start burning fat stores.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least noted that the same research team published an earlier, larger study in 2008.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t treat any of the approaches discussed as new.\u00a0 Good context on the range of stuff being done to treat toenails.", "answer": 1}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nBut tPA is not indicated and could hurt a patient's chances if they are having a hemorrhagic stroke, in which a blood vessel ruptures.\nEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department.\nPast research showed the sooner that a clot-busting tPA drug is given after an ischemic stroke - one in which a clot is blocking blood flow - the better patients fare.\nThis takes a certain amount of time from the patient's symptom onset which prompted the 9-1-1 call.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not adequately establish the novelty of the study or the findings. It does briefly allude to previous research: \u201cPast research showed the sooner that a clot-busting tPA drug is given after an ischemic stroke \u2013 one in which a clot is blocking blood flow \u2013 the better patients fare.\u201d\nThere have been around a dozen trials on mobile stroke units in recent years, appearing primarily in neurology journals. Some examples:", "answer": 0}, {"article": "Contact: Paul R. Sanberg at psanberg@health.usf.edu, Shinn-Zong Lin at shinnzong@yahoo.com.tw, or Associate Editor Samantha Portis at celltransplantation@gmail.com\n(June 1, 2016) - A two-year, multi-center clinical study with 167 patients with class III-IV refractory angina randomized to low and high dose CD34+ cells or placebo has revealed that patients who received either a high or low dose of CD34 -- a member of a family of proteins that have an impact on vascular-associated tissue -- cells had a significant reduction in angina frequency over patients who received placebo.\nThe Co-Editors-in-Chief for CELL TRANSPLANTATION are at the Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA and the Center for Neuropsychiatry, China Medical University Hospital, TaiChung, Taiwan.\n\"There are an increasing number of patients with advanced coronary artery disease that are not amenable to surgical or percutaneous revascularization,\" said study co-author Dr. Timothy D. Henry of the Cedars-Sinai Heart Institute.\nCD34+ cells drew the attention of researchers for possible therapeutic testing because recent studies pointed to the importance of CD34+ cell content in the bone marrow of patients with risk factors for coronary artery disease in predicting not only baseline, but also future exercise capacity.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As we noted under \u201cCompare Alternatives,\u201d there are a host of other angina treatments out there. Because they aren\u2019t addressed, it\u2019s not clear what makes this treatment novel. The release tells readers that some \u201cpatients with advanced coronary artery disease\u2026frequently have symptoms after having had standard therapies and are left with limited treatment options.\u201d The release also states that CD34+ treatment \u201cis an attractive treatment option\u201d for these patients. But it doesn\u2019t tell readers why. Nor does it mention how CD34+ differs from the other \u201climited treatment options.\u201d\nThe release also does not establish what makes CD34+ cells attractive as a treatment.\u00a0 It says \u201cbecause recent studies pointed to the importance of CD34+ cell content in the bone marrow of patients with risk factors for coronary artery disease.\u201d\u00a0 Risk factors do not mean the person will get the disease, nor is there a clear connection between bone marrow and the heart here.", "answer": 0}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story establish the true novelty of the approach?", "explanation": "A close call here. The story acknowledges previous research in this areas when it says, \u201cMouse and test-tube studies have shown that so-called nonselective beta blockers inhibit molecular pathways that promote tumor growth. Selective versions, designed to minimize side effects for heart patients, are less effective in hitting such targets.\u00a0Dr. Sood and his colleagues wondered if the same effect would be found in people.\u201d\u00a0That\u2019s good context, but the story could also have noted that a number of studies\u00a0have indeed examined the impact of beta-blocker use on ovarian cancer patients, and did not find the same prolonged survival rates that are reported on in this story. The researchers think that\u2019s because these earlier studies didn\u2019t distinguish between the two types of beta-blockers.", "answer": 1}, {"article": "The current study sets the stage for clinical trials in humans.\nBoth Nichols and Margaritis agreed: \"The table is now set to propose clinical trials that would treat people who suffer from FVII deficiency.\"\n\"This work is very exciting and promising,\" said Nichols, who added, \"The FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\n\"These dogs have the type of mutation found in the majority of patients with this disorder, so this approach could lead to a sustained gene therapy in people.\"\n\"We developed a unique animal model of this disease after identifying dogs with naturally occurring factor VII deficiency,\" said Margaritis.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This gene therapy is novel for this particular condition. The news release should also be commended for pointing out that a similar gene therapy approach has been tested by the same researchers for hemophilia. It\u2019s admirable that they are not overselling the novelty of this approach by referencing their own previous work in related areas.", "answer": 1}, {"article": "Elder's team found the right amount of sleep and stress reduction at the start of the trial predicted successful weight loss.\nIn fact, although diet and exercise are the usual prescription for dropping pounds, high stress and too little sleep (or too much of it) can hinder weight loss even when people are on a diet, the researchers report.\n\"If sustained, the dietary choices made by people undergoing short sleep could predispose them to obesity and increased risk of cardiovascular disease,\" the researchers wrote in an American Heart Association news release.\nAnd the factors that promote health -- eating well, being active, not smoking, sleeping enough, controlling stress, to name a few --promote all aspects of health,\" he added.\nTUESDAY, March 29, 2011 (HealthDay News) -- If you're looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list, say researchers from Kaiser Permanente's Center for Health Research in Portland.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was framed as taking a broader perspective when contemplating weight loss and including other lifestyle factors which can affect food intake and exercise.\u00a0 Better than its LA Times competition, at least this story nodded in the direction of one other recent study on sleep and weight, thereby conveying that the newer study is not the only research on this topic.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this is an experimental drug and not the only one of its kind in development. ", "answer": 1}, {"article": "Former smokers who had accumulated 30 pack-years were included only if they had stopped smoking within the previous 15 years.\n\u201cI\u2019m concerned that some radiologists might be early in that learning curve and some patients may be harmed because of it.\u201d\n\nWhile the study found a benefit to scanning a specific group of high-risk smokers, that doesn\u2019t mean other groups will get the same benefit, says Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York.\nThe day the government announced the study results, Westside Medical Imaging of Beverly Hills, Calif., issued a press release saying that the study \u201cshould once and for all settle the controversy\u201d about whether CT lung scans save lives.\nIn an interview, Dr. Lepor said that he only offers lung scans to those at high risk, and that he turns people away who are at low risk but want the scan anyway because \u201cthey just want to know.\u201d\n\nDr. Lepor said it would be \u201cimprudent\u201d not to incorporate the latest study data into his practice right away.\nWe know from our own anecdotes that we have saved a lot of lives.\u201d\n\nDr. Lepor said that he had just met a woman who had smoked for 50 years and was concerned about her risk.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that some were already promoting the study\u2019s findings in news releases saying that the study \u201cshould once and for all settle the controversy\u201d about whether CT lung scans save lives.\u00a0 But it quickly countered that claim with observations from Dr. Otis Brawley of the American Cancer Society who said that he was worried that the few early press releases and radio advertisements are just the beginning of widespread promotion of screening lung scans.\n\u201cIt was sort of ominous to be working Sunday evening in my home office and this thing comes on the radio,\u201d he said. \u201cA lot of people run out when there is a new announcement and get the new test. We\u2019re very frightened some people are going to be harmed because of this.\u201d\n", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story establish the true novelty of the approach?", "explanation": "It's clear from the story that this is a relatively new drug in a new class of drugs for obesity/diabetes treatment, and that this research is looking at a possible new use for the drug.\u00a0 ", "answer": 1}, {"article": "\"Studies comparing stage of disease with outcome following surgery suggest that death rates frompancreatic cancer would be reduced if the disease were diagnosed at an earlier stage,\" said Dr. Raghu Kalluri, chair of cancer biology at M.D.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\nThe pancreas is located deep within the body, so early tumors cannot be seen or felt during routine physical exams.\nPancreatic cancer has one of the lowest survival rates of any cancer, with only 4 percent of patients surviving five years after diagnosis.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggests that if the screening test were developed, it would be a more effective tool for detecting pancreatic cancer. Again, it\u2019s a big \u201cif,\u201d but the story doesn\u2019t hide that fact \u2013 to its credit.", "answer": 1}, {"article": "DANVILLE, Calif., April 11, 2018 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira\u00ae treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment.\nTheir first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic.\nTreatment is authorized and completed under the supervision of a licensed healthcare provider.\nFreespira is both easy to use and effective.\nOnce a licensed healthcare provider authorizes the treatment and after a single training session, the patient uses Freespira at home, performing two 17-minute breathing sessions a day over a four-week period, after which the treatment is complete.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not provide proof of the claim that there is a \u201cnew\u201d clinical research study supporting the headline.", "answer": 0}, {"article": "\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nThese kinds of carbs bypass the small intestine (where most food is digested) and head to the large intestine (also known as the colon) to be metabolized.\n\u201cThe ensuing structure of those bonds during the cooling process is what makes them resistant to then being digested in the small intestine,\u201d Arciero says.\nThere, they\u2019re fermented and turned into short-chain fatty acids, which the body burns as energy.\nBut the new evidence suggests that it may help control weight by altering body composition and increasing satiety.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that these types of starches are being studied in a variety of ways.", "answer": 1}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report makes clear, with some level of detail, precisely how common c-sections and elective c-sections are. ", "answer": 1}, {"article": "The study was funded by the Veterans Health Administration's Health Services Research and Development Service\nThe sharp rise in opioid addiction in recent years - often among people who started taking the painkillers as treatment for acute or chronic pain -- has made the search for effective non-drug pain treatment options even more urgent, Ilgen notes.\n\"We want to take the focus off pain and put it onto functioning, and finding pleasurable ways to spend time,\" Ilgen says.\nAll 129 patients in the study, most of them men in their 40s and 50s, were receiving outpatient addiction treatment in a CBT-based, non-abstinence setting at the Ann Arbor VA. Half were randomly assigned to ImPAT sessions, the other half to support groups of peers, led by a therapist, where pain and addiction could be discussed.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that the two treatment techniques that constitute ImPAT are rarely used jointly, but are both fairly common in pain treatment settings. However, as the release notes, pain treatment clinics and centers often decline to work with patients who have substance abuse problems.", "answer": 1}, {"article": "Rothwell and his colleagues published their findings Dec. 7 in the online edition of The Lancet.\nThe current observations follow prior research conducted by the same study team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the risk of dying from colorectal cancer by a third.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\nAnd while cautioning that more research is necessary to build on this \"proof of principle,\" the authors suggested that people who embark on a long-term, low-dose aspirin regimen in their late 40s and 50s are probably the ones who stand to benefit the most.\nThe protective impact of low-dose aspirin on stomach and colorectal cancer death was not seen until 10 years out, and for prostate cancer, the benefits first appeared 15 years down the road.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not try to oversell the novelty of using aspirin to prevent cancer. However, it\u00a0should have\u00a0provided more discussion of\u00a0the extensive body or\u00a0previous research on aspirin and cancer. Previous trials and observational\u00a0studies have come to conflicting conclusions about the benefits of aspirin for cancer prevention, and this new study needs to be viewed in the context of this existing research.", "answer": 1}, {"article": "Other New York counties took similar actions after New York City\u2019s measure was enacted.\nStill, the study can\u2019t say the trans fat restrictions caused fewer admissions in those counties.\nWhile admissions for heart attacks and strokes fell after 2002 in all the counties, the drop was more substantial in those that enacted trans fat restrictions, the authors found.\nIn 2006, there were 753 hospital admissions for heart attack or stroke per 100,000 people in counties that never enacted restrictions compared to 726 per 100,000 people in counties that put restrictions in place.\nSimilarly, admissions for strokes were about 4 percent lower in counties with restrictions, but that finding could be due to chance.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The text notes that earlier research\u00a0looked only at reductions in mortality; this new study expands that effort by focusing on hospitalizations.", "answer": 1}, {"article": "Dr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nWith about 300 million anesthesia injections given by dentists each year, company executives say the drug could easily achieve sales of hundreds of millions of dollars a year.\nIn two trials of 484 patients in total, people were given either OraVerse or a sham injection.\nOraVerse does the opposite, dilating the blood vessels and speeding up blood flow so the anesthetic can be carried away.\n\u201cWe aren\u2019t reversing the local anesthesia,\u201d said Dr. Paul A. Moore, chairman of anesthesiology at the University of Pittsburgh School of Dental Medicine, who is an adviser to Novalar.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does a good job of explaining that the drug itself has been in use for a long time to treat severe hypertension, but that its use to reverse the effects of dental anesthesia is novel. ", "answer": 1}, {"article": "For every one point increase in processed foods consumption, they lost 1.67 points in IQ.\nConversely, every one point increase in healthy eating translated into a 1.2 point increase in IQ, the researchers found.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\n\"This can have a series of deleterious effects, including decreased cognitive ability, poor behavior and social skills,\" she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This study is part of a fast-growing field of research into the effects of early childhood nutrition on a variety of later health outcomes. The story could have mentioned this larger context, but it didn\u2019t.", "answer": 0}, {"article": "It is sort of a window into the lung.\u201d\n\nCigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\nMost patients are not diagnosed until it has spread and can no longer be treated.\nThe main gene is called PI3K and it affects a pathway of other genes, Bild, Avrum Spira of Boston University and colleagues reported.\nThese were patients with precancerous lesions in their lungs called dysplasia.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "       \n \nThe story indicates that PI3K had \"long been suspected in lung cancer.\" \n ", "answer": 1}, {"article": "Doctors currently diagnose colds and flus through a patchwork of testing, observation and process of elimination.\nIt tests for a dozen viruses, including several types of influenza, two types of respiratory syncytial virus, or RSV, three types of parainfluenza, adenovirus and even rhinovirus, which causes the common cold.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nThe downside is that the test is expensive, about $300 to $400, but is covered by most insurers.\nCurrently available tests can yield results in a half hour, though accuracy varies and they typically screen for only one or two viruses.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The xTag test is novel and the article handles this nicely.\u00a0 It is the only FDA approved product that can detect multiple viral strains that can cause acute respiratory diseases.", "answer": 1}, {"article": "(Editing by Jon Loades-Carter)\nBapineuzumab \u2014 being developed by Pfizer Inc (PFE.N), Irish drugmaker Elan Corp ELN.I and Johnson & Johnson (JNJ.N) \u2014 is a potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\n\u201cIt demonstrated that the drug has an effect on the pathological hallmark of Alzheimer\u2019s disease,\u201d lead researcher Juha Rinne from Finland\u2019s University of Turku told Reuters.\nMost advanced drugs, like bapineuzumab, have focused on removing clumps of amyloid plaques, which are thought to stop brain cells from functioning properly.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The drug reported on, bapineuzamab, is currently the focus of a number of clinical trials, many of which are recruiting participants. \u00a0(www.clinicaltrials.gov). \u00a0The focus of this story was on a very tiny study which was more about methodology for assessing Alzheimer\u2019s disease. \u00a0So while the story made it seem like it was reporting on a study of a novel drug, it failed to mention the much larger studies of this drug that are currently in the works.", "answer": 0}, {"article": "Participants in the study familiarized themselves with the workstations during one visit.\n\u201cExercise is a good way to counteract the negative effects of sitting, but just incorporating physical activity into one part of our day may not be enough to overcome the damage caused by prolonged sitting and an otherwise sedentary lifestyle.\u201d\n\nBecause the workday is a major contributor to sedentary behavior, with more than 20 percent of workers in the U.S. reporting more than 8 hours each day, tactics that promote workstation activity have emerged in recent years, including standing desks, as well as dynamic pedal and treadmill workstations.\n\u201cWe expected to see the metabolic rate increase with each progressive stage, but instead found that metabolic rates from movement while seated were either equal to or higher than rates while standing.\u201d\n\nHorswill says the study needs to be further validated, but that the findings should be especially applicable to individuals poised to benefit from NEAT but unable to access popular standing desks because of injury, disability or discomfort.\nThe device, which is commercially available, was a movable footrest, suspended from the underside of the desk, which enabled the feet to swing, twist or teeter.\nThe findings are published in WORK, a journal affiliated with the Canadian Association of Occupational Therapists and endorsed by the International Ergonomics Association.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This study is one in a growing body of research about non-exercise activity thermogenesis (NEAT), which is the energy we expend in our daily lives when not sleeping, eating, or doing sports-like levels of exercise. NEAT incorporates our fidgeting, our daily walking around, even our keyboard typing. This study is novel in that it found that, counter-intuitively, leg exercises while sitting might increase metabolism more than using a standing desk. But the operative word here is \u201cmight\u201d \u2013based on the quality of evidence the news release was likely premature, and did not highlight the many weaknesses in the study.", "answer": 1}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nThe story refers to the background of research that suggested certain brain regions might have a connection to the reading ability of people with dyslexia; and it makes clear what is new about the findings of this study.", "answer": 1}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\n\"They did well and beat their lung cancer,\" Adusumilli says, proving that when it comes to surgery for early stage lung cancer, age should not be a limiting factor.\nSurgery isn't the answer for all older lung cancer patients, according to Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society.\n\"We shouldn't allow numerical age to be the deciding factor,\" Lichtenfeld says.\nThe study looked at more than 2,000 patients with Stage 1 non-small cell lung cancer who had surgery to remove their tumor.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article implicitly suggests\u00a0the novelty of the study is\u00a0that it overturns conventionally held beliefs about the benefits of\u00a0surgery in older lunger cancer patients.\u00a0But that\u2019s not really the case.\nThe researchers chief\u00a0conclusion was \u201cIn patients who undergo curative-intent resection of stage I NSCLC, noncancer-specific mortality is a significant competing event, with an increasing impact as patient age increases.\u201d In plain language, many older lung cancer patients die of non-cancer problems. This doesn\u2019t prove that lung cancer surgery is beneficial and leads to a longer, better lifespan than\u00a0other options. Nor does it prove the surgery was the best choice.", "answer": 0}, {"article": "First published on September 5, 2007 at 12:00 am\nThe robots have proven popular for urologic, gynecologic and some general surgery, Pappas said, but few coronary surgeons use them for valve repairs and fewer still do bypass procedures.\nMany who trained to use robots to do coronary bypass run out of patience after three or four procedures, Jeevanandam said, which is why he decided to hire Dr. Sudhir Srivastava, who performed hundreds of robotic bypasses while working at a center in Odessa, Texas.\nWhile surgical robots have been available for most of this decade, few are used to do cardiac bypass surgery, even though that was their focus when the machines were introduced.\nThe robot - not a kind of mechanical being but a system that enables a surgeon at a control panel to manipulate microtools - has proved more challenging to integrate into coronary bypass surgery than expected, illustrating how technological advancements can be difficult to readily adapt.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the article implies that use of the robotic device for heart bypass surgeries is rare, insufficient data is provided to help readers understand how rare it is. Since the report says the machines have been in wide use most of this decade, it should have been clearer about how many hospitals use the machines for bypass surgery, what else they use them for and\u00a0which patients are considered best candidates for it. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion.\u00a0 ", "answer": 1}, {"article": "Bangalore said this is critically important because \"compliance is big issue with our patients.\"\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\nThe one difference they found was that ARBs tend to be better tolerated by patients, meaning that they have fewer side effects or result in fewer adverse events.\nThe idea that ACE inhibitors are more effective than ARBs was based on comparing studies on ACE inhibitors going as far back as the 1980s and into the 1990s with newer studies on ARBs in the 2000s.\nMost guidelines set forth by the major medical groups suggest starting a patient with an ACE inhibitor first, but the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) considers ACE inhibitors and ARBs to be equal.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here is simply that this meta-analysis is aimed at clarifying uncertainty surrounding the comparison of these two classes of drugs and their efficacy in treating cardiovascular disease.\u00a0 The prevalence of this condition within the population makes it a topic of broad interest, both among the public and among the professionals who treat them.", "answer": 1}, {"article": "Allowing more basic emergency medical service (EMS) staff to administer naloxone could reduce drug overdose deaths that involve opioids, according to a Centers for Disease Control and Prevention (CDC) study, \u201cDisparity in Naloxone Administration by Emergency Medical Service Providers and the Burden of Drug Overdose in Rural Communities,\u201d published in the American Journal of Public Health.\nLearn more at www.cdc.gov/DrugOverdose.\nIn 2013, more than 16,000 deaths in the United States involved prescription opioids, and more than 8,000 others were related to heroin.\nNaloxone is a prescription drug that can reverse the effects of prescription opioid and heroin overdose, and can be life-saving if administered in time.\nIn general, the rate of opioid overdose death was 45 percent higher in rural areas compared with urban areas.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It would have been helpful to put the research in the context of previous work. Naloxone is not new. But are the results being reported new and surprising? What was known about naloxone use among EMTs previously?", "answer": 0}, {"article": "HIFs activate programs that promote the development of blood vessels, facilitate oxygen delivery and promote efficient nutrient utilization.\n\"The approaches we have taken pave the way for identifying drug candidates for other proteins that have traditionally been considered undruggable.\"\nThe findings show that HIF-2 is a promising target to combat kidney cancer, said Dr. Brugarolas, senior author and a Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern.\nResearchers surprisingly found a subset of tumors that do not respond to the drug, but were able to identify biomarkers that, once verified, would help determine which patients are more likely to benefit from HIF-2 therapies.\nTexas has the fifth highest rate of this cancer in the U.S.\n\nHIFs or hypoxia-inducible factors, like HIF-2, allow the body's cells to adjust to low-oxygen environments.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It is pretty clear this is a novel approach, and we do get some explanation of why HIF-2 may have been disregarded in the past.", "answer": 1}, {"article": "\u201cThe treatment of cachexia just doesn\u2019t exist.\n\u201cThis same calcium signal also activates signaling pathways to increase skeletal muscle endurance and also skeletal muscle size.\u201d\n\nSah\u2019s research team hypothesized that low level calcium cycling induced by these natural compounds might promote improved exercise capacity and overall metabolic health associated with healthy muscle mass.\nIn pre-clinical studies, compounds in thyme and oregano have demonstrated a greater than 37 percent increase in exercise tolerance and a 15 percent increase in muscle mass of certain body muscles.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "If combating cachexia were as simple as using compounds from\u00a0ordinary spices, then this would be adequately novel. But neither the release nor the research as yet are available tend to bear that out. The work is done in animals, not humans. The compounds are not identified. And the explanation of benefits from those compounds is inadequate for readers to have confidence in these claims.", "answer": 0}, {"article": "Cao hopes her study will continue to broaden the body of research to include cancer-related deaths overall.\nTherefore the findings are believed to be very robust, and suggest that aspirin, which is widely available, cheap and has limited toxicity, has the potential to have widespread benefit on cancer mortality for breast, colon, lung and prostate cancer.\"\n\"It is good to remember, though, if a person wants to take a low-dose aspirin, especially if a person has had cancer, they will want to have an initial conversation with their doctor first.\"\n\"There has been a great deal of interest in understanding the possible benefits associated with common drugs,\" Tamimi said in an emailed statement.\nThe risk of dying from cancer was 7% lower for women and 15% lower for men who took aspirin regularly, compared with those who didn't take a regular dose.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t clearly establish what\u2019s new about this research\u2013how, exactly, does it add to what\u2019s already known about aspirin and cancer risk?\nThe news release indicates the novel finding is this: \u201cThese findings suggest that aspirin\u2019s established benefits in cardiovascular disease and colorectal cancer reduction may extend to other common causes of death, including several major cancers.\u201d", "answer": 0}, {"article": "The paper \"Real-time imaging of the resection bed using a handheld probe to reduce incidence of microscopic positive margins in cancer surgery\" is available online at http://cancerres.\n\"It is likely better to check to see if any residual tumor cells might be left behind, rather than checking the tissue mass that was taken out.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\nIn the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later.\nA solid tumor may be easily identifiable, but the tissue around the main body of the tumor, known as the margin, may contain cancerous cells as well.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As noted above, the release could have mentioned a competing device that has already been found able to distinguish pretty well between normal and cancerous tissue, but not in real time with a portable device in the operating room. However, the release does quote one of the researchers who establishes what is new here:\u00a0\u201cFor the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery.\u201d We\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "\u201cThey often don\u2019t appreciate the downside of screening,\u201d Dr. Brooks said, \u201cand they don\u2019t appreciate the delay in benefit.\u201d In addition, Dr. Brooks said, primary care doctors often \u201coverestimate the likelihood that early detection of prostate cancer will lead to survival benefits.\u201d\n\nAdded to that, Dr. Brooks said, is the length of time it takes to discuss the pros and cons of screening with patients.\nThey note that prostate cancer is a common cancer, found in most men\u2019s prostates on autopsy, although often the men had no idea they had it.\nBut if a man has been screened year after year, it can be hard to suggest he stop because he may not live much longer.\nEven younger men should weigh the harms of screening, says Dr. Lisa Schwartz of Dartmouth Medical School.\nThey often are afraid they could be sued if they do not screen and a man is found to have a lethal cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that PSA testing is readily available and routinely used by the percentages of men indicated in the story.", "answer": 1}, {"article": "On the surface, this seems to contradict a U.S. trend toward holding off on surgery and monitoring men who have low-risk cancers with what's called \"active surveillance.\"\nLike every new study of prostate cancer, the results need to be carefully parsed.\nAnd it applied to men with tumors considered low-risk, meaning they have a relatively low Gleason score, a marker of tumor aggressiveness.\nAll of them had early-stage prostate cancer at the beginning.\nUnfortunately, there haven't been any large studies in which prostatectomy and radiation therapy have been compared in patients with early-stage prostate cancer who have been randomly assigned to one or the other.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It was clear from this story that the approaches to managing prostate cancer detailed in the study reported on are neither new nor novel.", "answer": 1}, {"article": "There are clear philosophical differences.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\n\u201cBeyond adding an element of suspense, this strategy allowed us to come to unbiased conclusions.\u201d\n\nAfter Lockwood found that recent studies suggest that elective inductions at 39 weeks decrease Caesarean delivery rates and might reduce the rate of infant and maternal complications, what was supposed to be a debate proceeded as a discussion in support of induction.\nThe question was presented in May at the yearly ACOG meeting in Washington: \u201cWhy not induce everyone at 39 weeks?\u201d Two doctors had been asked to debate: Errol Norwitz, chairman of obstetrics and gynecology at Tufts University School of Medicine, and Charles Lockwood, dean of the Morsani College of Medicine at the University of South Florida.\nRather, he said, the latest literature suggests that the drugs available to soften the cervix in preparation for contractions help to decrease the Caesarean risk, adding a small caveat: For a small number of first-time mothers with \u201cunfavorable, long and hard cervixes\u201d \u2014 as opposed to cervixes that are soft and receptive to induction \u2014 the risk of Caesarean is increased.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story refers to recent studies, but again there are no details provided, so readers are not told what \u201crecent\u201d means. Have the studies been around for years, but just escaped the notice of the featured physicians until they checked the literature in order to prepare for their panel session? Or is there really some important new evidence that wasn\u2019t available when ACOG and other groups issued the latest version of their recommendations about inducing labor? The story doesn\u2019t answer those questions.", "answer": 0}]